# C_2017215EN.01002101.xml

| 5.7.2017 | EN | Official Journal of the European Union | C 215/21 |
| -------- | -- | -------------------------------------- | -------- |

---

EU ACTION PLAN ON DRUGS 2017-2020

(2017/C 215/02)

CONTENTS

Introduction

| 1. | Drug demand reduction | |
| -- | --------------------- | |

| 2. | Drug supply reduction | |
| -- | --------------------- | |

| 3. | Coordination | |
| -- | ------------ | |

| 4. | International cooperation | |
| -- | ------------------------- | |

| 5. | Information, research, monitoring and evaluation | |
| -- | ------------------------------------------------ | |

ANNEX I — 15 over-arching indicators for the EU Action Plan on Drugs 2017-2020

ANNEX II — Glossary of acronyms

Introduction

The use of illicit drugs and the misuse of drugs generally, is a major problem for individuals, families and communities across Europe. Apart from the health and social implications of drug misuse, the illicit drugs market constitutes a major element of criminal activity across European society and, indeed, on a global level.

In December 2012, the Council adopted the EU Drugs Strategy for 2013-2020. The Strategy aims to contribute to a reduction in drug demand and drug supply within the EU. It also aims to reduce the health and social risks and harms caused by drugs through a strategic approach that supports and complements national policies, that provides a framework for coordinated and joint actions and that forms the basis and political framework for EU external cooperation in this field. This will be achieved through an integrated, balanced and evidence-based approach.

The objectives of the Strategy are:

| — | to contribute to a measurable reduction of the demand for drugs, of drug dependence and of drug-related health and social risks and harms, |
| - | ------------------------------------------------------------------------------------------------------------------------------------------ |

| — | to contribute to a disruption of the illicit drugs market and a measurable reduction of the availability of illicit drugs, |
| - | -------------------------------------------------------------------------------------------------------------------------- |

| — | to encourage coordination through active discourse and analysis of developments and challenges in the field of drugs at EU and international level, |
| - | --------------------------------------------------------------------------------------------------------------------------------------------------- |

| — | to further strengthen dialogue and cooperation between the EU and third countries, international organisations and fora on drug issues, |
| - | --------------------------------------------------------------------------------------------------------------------------------------- |

| — | to contribute to a better dissemination of monitoring, research and evaluation results and a better understanding of all aspects of the drugs phenomenon and of the impact of interventions in order to provide a sound and comprehensive evidence base for policies and actions. |
| - | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |

This EU Drugs Action Plan, like the EU Drugs Strategy, is based on the fundamental principles of EU law and it upholds the founding values of the Union — respect for human dignity, liberty, democracy, equality, solidarity, the rule of law and human rights. It is also based on the UN Conventions that provide the international legal framework to address, inter alia, the use of illicit drugs, as well as on the Universal Declaration on Human Rights.

The Plan sets out the Actions that will be implemented to achieve the objectives of the Strategy. Actions are set out under the two policy areas of the Strategy:

| — | drug demand reduction, and |
| - | -------------------------- |

| — | drug supply reduction, |
| - | ---------------------- |

and the three cross-cutting themes of the Strategy:

| — | coordination, |
| - | ------------- |

| — | international cooperation, and |
| - | ------------------------------ |

| — | information, research, monitoring and evaluation. |
| - | ------------------------------------------------- |

Actions are aligned to objectives of the EU Drugs Strategy 2013-2020. In drawing up the actions, account was taken of the need to be evidence-based, scientifically sound, realistic, time-bound, available and measurable with a clear EU relevance and added value. This Action Plan indicates timetables, responsible parties, indicators and data collection/assessment mechanisms.

Based on existing reporting mechanisms, a number of over-arching indicators are set out in Annex I. These facilitate the measurement of the overall effectiveness of this EU Drugs Action Plan and do not involve an additional reporting burden. A number of these are referenced, as appropriate, across the Plan. Furthermore, throughout the Plan, indicators are set out that draw on programme, evaluative and other data sources. Utilisation of these indicators is dependent on data collection processes in each Member State or at EU institution level.

In line with the Strategy stipulation that its detailed implementation should be set out in two consecutive Action Plans, the first Action Plan implementing the current drugs strategy was adopted in 2013 and expired in 2016. In 2016, an external mid-term assessment of the EU Drugs Strategy and the implementation of the EU Drugs Action Plan 2013-2016 was completed. The evaluation concluded that most of the actions foreseen in this Action Plan were concluded or in progress. The results of the evaluation also demonstrated the need for the second Action Plan to implement the EU Drugs Strategy 2013-2020, which should be the updated version of the EU Action Plan on Drugs 2013-2016. The EU Drugs Action Plan 2017-2020 as provided below takes into account the results of this evaluation and the major changes in drug situation and policies since the adoption of the last Action Plan.

1.   Drug demand reduction

Contribute to a measurable reduction in the use of illicit drugs, in problem drug use, in drug dependence and in drug-related health and social harms as well as contributing to a delay in the onset of drug use

| Objective | Action | Timetable | Responsible party | Indicator(s) | Data collection/assessment mechanisms |
| ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------ | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| 1.
Prevent drug use and, secondly, delay the onset of drug use | 1. | Prevent drug use and, secondly, delay the onset of drug use | 1.
Improve the availability and effectiveness of evidence-based( 1 ) prevention measures that take account of risk and protective factors as outlined below
a.
population factors such as age; gender; education, cultural and social factors; b.
situational factors such as homelessness; migration and asylum seeking, drug use in nightlife and recreational settings; the workplace; and driving under the influence of drugs; and c.
individual factors such as mental health; behaviour and psychosocial development; and other factors known to affect individual vulnerability to drug use such as genetic influences and family circumstances | 1. | Improve the availability and effectiveness of evidence-based( 1 ) prevention measures that take account of risk and protective factors as outlined below
a.
population factors such as age; gender; education, cultural and social factors; b.
situational factors such as homelessness; migration and asylum seeking, drug use in nightlife and recreational settings; the workplace; and driving under the influence of drugs; and c.
individual factors such as mental health; behaviour and psychosocial development; and other factors known to affect individual vulnerability to drug use such as genetic influences and family circumstances |
| 1. | Prevent drug use and, secondly, delay the onset of drug use | | | | |
| 1. | Improve the availability and effectiveness of evidence-based( 1 ) prevention measures that take account of risk and protective factors as outlined below
a.
population factors such as age; gender; education, cultural and social factors; b.
situational factors such as homelessness; migration and asylum seeking, drug use in nightlife and recreational settings; the workplace; and driving under the influence of drugs; and c.
individual factors such as mental health; behaviour and psychosocial development; and other factors known to affect individual vulnerability to drug use such as genetic influences and family circumstances | a. | population factors such as age; gender; education, cultural and social factors; | b. | situational factors such as homelessness; migration and asylum seeking, drug use in nightlife and recreational settings; the workplace; and driving under the influence of drugs; and |
| a. | population factors such as age; gender; education, cultural and social factors; | | | | |
| b. | situational factors such as homelessness; migration and asylum seeking, drug use in nightlife and recreational settings; the workplace; and driving under the influence of drugs; and | | | | |
| c. | individual factors such as mental health; behaviour and psychosocial development; and other factors known to affect individual vulnerability to drug use such as genetic influences and family circumstances | | | | |
| — | Over-arching indicators 1, 11, 12 | | | | |
| — | Availability and level of provision at MS level of evidence-based universal and environmental prevention measures | | | | |
| — | Availability and level of provision at MS level of evidence-based targeted prevention measures, including family and community based measures | | | | |
| — | Availability and level of provision at MS level of evidence-based indicated prevention measures | | | | |
| | 2.
In addition to the prevention of drug use, strengthen and better target prevention and diversionary measures to delay the age of first use of illicit drugs and other psychoactive substances | 2. | In addition to the prevention of drug use, strengthen and better target prevention and diversionary measures to delay the age of first use of illicit drugs and other psychoactive substances | Ongoing | MS |
| 2. | In addition to the prevention of drug use, strengthen and better target prevention and diversionary measures to delay the age of first use of illicit drugs and other psychoactive substances | | | | |
| — | Over-arching indicators 1, 5, 11, 12 | | | | |
| — | Availability and level of provision at MS level of evidence-based prevention and diversionary measures that target young people in family, community, and formal/non-formal education settings | | | | |
| | 3.
Exchange of best practices of all forms of prevention actions targeting children and young people, parents and, educational environments whilst also taking into account gender-specific needs, including educational activities, community based programmes, programmes using internet and social media. | 3. | Exchange of best practices of all forms of prevention actions targeting children and young people, parents and, educational environments whilst also taking into account gender-specific needs, including educational activities, community based programmes, programmes using internet and social media. | Ongoing | MS
EMCDDA |
| 3. | Exchange of best practices of all forms of prevention actions targeting children and young people, parents and, educational environments whilst also taking into account gender-specific needs, including educational activities, community based programmes, programmes using internet and social media. | | | | |
| — | Overview of exchanges of best practices between MS | | | | |
| — | Positive evaluations of behavioural outcomes of best practice interventions (where available) | | | | |
| | 4.
Raise awareness of the risks and consequences associated with the use of illicit drugs and other psychoactive substances and improve skills and competences for preventing drug use. | 4. | Raise awareness of the risks and consequences associated with the use of illicit drugs and other psychoactive substances and improve skills and competences for preventing drug use. | Ongoing | MS
COM
EMCDDA |
| 4. | Raise awareness of the risks and consequences associated with the use of illicit drugs and other psychoactive substances and improve skills and competences for preventing drug use. | | | | |
| — | Over-arching indicators 5, 12 | | | | |
| — | Level of awareness in general and youth populations of healthy lifestyles and of the risks and consequences of the use of illicit drugs and other psychoactive substances and level of the skills and competences of those involved in the prevention of drug use | | | | |
| | 5.
Enable a more informed response to the challenge of the misuse of psychoactive medicines. | 5. | Enable a more informed response to the challenge of the misuse of psychoactive medicines. | 2017-2020 | MS
Council WP (HDG Pharmaceuticals and Medical Devices)
EMA
EMCDDA |
| 5. | Enable a more informed response to the challenge of the misuse of psychoactive medicines. | | | | |
| — | Number of initiatives that focus on the promotion of appropriate use of psychoactive medicines | | | | |
| — | Collation of evidence and international examples on how to reduce the risks of diversion and misuse of psychoactive medicines | | | | |
| — | Number of courses for medical practitioners and other health care professionals in the use of medication to control pain and treat suffering | | | | |
| 2.
Enhance the effectiveness of drug treatment and rehabilitation, including services for people with co-morbidity, to reduce the use of illicit drugs; problem drug use; the incidence of drug dependency and drug-related health and social risks and harms and to support the recovery and social re/integration of problematic and dependent drug users. | 2. | Enhance the effectiveness of drug treatment and rehabilitation, including services for people with co-morbidity, to reduce the use of illicit drugs; problem drug use; the incidence of drug dependency and drug-related health and social risks and harms and to support the recovery and social re/integration of problematic and dependent drug users. | 6.
Develop and expand the diversity, availability, coverage and accessibility of evidence-based comprehensive and integrated treatment services. Ensure that these services address polydrug use (combined use of illicit and licit substances including psychoactive medicines, alcohol and tobacco) and the emerging needs of the ageing drug-using population and gender-specific issues.
a.
Implement and improve training for health care and social care professionals in addictive behaviours. b.
Develop and implement early detection and intervention, brief intervention and treatment programmes for children and young people using drugs. | 6. | Develop and expand the diversity, availability, coverage and accessibility of evidence-based comprehensive and integrated treatment services. Ensure that these services address polydrug use (combined use of illicit and licit substances including psychoactive medicines, alcohol and tobacco) and the emerging needs of the ageing drug-using population and gender-specific issues.
a.
Implement and improve training for health care and social care professionals in addictive behaviours. b.
Develop and implement early detection and intervention, brief intervention and treatment programmes for children and young people using drugs. |
| 2. | Enhance the effectiveness of drug treatment and rehabilitation, including services for people with co-morbidity, to reduce the use of illicit drugs; problem drug use; the incidence of drug dependency and drug-related health and social risks and harms and to support the recovery and social re/integration of problematic and dependent drug users. | | | | |
| 6. | Develop and expand the diversity, availability, coverage and accessibility of evidence-based comprehensive and integrated treatment services. Ensure that these services address polydrug use (combined use of illicit and licit substances including psychoactive medicines, alcohol and tobacco) and the emerging needs of the ageing drug-using population and gender-specific issues.
a.
Implement and improve training for health care and social care professionals in addictive behaviours. b.
Develop and implement early detection and intervention, brief intervention and treatment programmes for children and young people using drugs. | a. | Implement and improve training for health care and social care professionals in addictive behaviours. | b. | Develop and implement early detection and intervention, brief intervention and treatment programmes for children and young people using drugs. |
| a. | Implement and improve training for health care and social care professionals in addictive behaviours. | | | | |
| b. | Develop and implement early detection and intervention, brief intervention and treatment programmes for children and young people using drugs. | | | | |
| — | Over-arching indicators 1, 6, 11 | | | | |
| — | Extent and diversity of evidence-based comprehensive and integrated treatment services at MS level including those which address polydrug use and the needs of the ageing drug-using population | | | | |
| — | MS data on treatment retention and outcomes | | | | |
| | 7.
Expand the provision of rehabilitation/reintegration and recovery services with an emphasis on services that:
a.
focus on providing a continuum of care through case management and interagency collaboration for individuals; b.
focus on supporting the social re/integration (including the employability and housing) of problem and dependent drug users including prisoners and ageing drug users, where relevant; c.
Strengthen the diagnostic process and the treatment of psychiatric and physical co- morbidity involving drug use, for e.g. with rapid testing for hepatitis B and C and HIV as well as other sexually transmitted infections and tuberculosis; d.
take account of gender-specific needs; and e.
reach out to vulnerable communities/populations. | 7. | Expand the provision of rehabilitation/reintegration and recovery services with an emphasis on services that:
a.
focus on providing a continuum of care through case management and interagency collaboration for individuals; b.
focus on supporting the social re/integration (including the employability and housing) of problem and dependent drug users including prisoners and ageing drug users, where relevant; c.
Strengthen the diagnostic process and the treatment of psychiatric and physical co- morbidity involving drug use, for e.g. with rapid testing for hepatitis B and C and HIV as well as other sexually transmitted infections and tuberculosis; d.
take account of gender-specific needs; and e.
reach out to vulnerable communities/populations. | a. | focus on providing a continuum of care through case management and interagency collaboration for individuals; |
| 7. | Expand the provision of rehabilitation/reintegration and recovery services with an emphasis on services that:
a.
focus on providing a continuum of care through case management and interagency collaboration for individuals; b.
focus on supporting the social re/integration (including the employability and housing) of problem and dependent drug users including prisoners and ageing drug users, where relevant; c.
Strengthen the diagnostic process and the treatment of psychiatric and physical co- morbidity involving drug use, for e.g. with rapid testing for hepatitis B and C and HIV as well as other sexually transmitted infections and tuberculosis; d.
take account of gender-specific needs; and e.
reach out to vulnerable communities/populations. | a. | focus on providing a continuum of care through case management and interagency collaboration for individuals; | b. | focus on supporting the social re/integration (including the employability and housing) of problem and dependent drug users including prisoners and ageing drug users, where relevant; |
| a. | focus on providing a continuum of care through case management and interagency collaboration for individuals; | | | | |
| b. | focus on supporting the social re/integration (including the employability and housing) of problem and dependent drug users including prisoners and ageing drug users, where relevant; | | | | |
| c. | Strengthen the diagnostic process and the treatment of psychiatric and physical co- morbidity involving drug use, for e.g. with rapid testing for hepatitis B and C and HIV as well as other sexually transmitted infections and tuberculosis; | | | | |
| d. | take account of gender-specific needs; and | | | | |
| e. | reach out to vulnerable communities/populations. | | | | |
| — | Over-arching indicator 11 | | | | |
| — | Extent of increase in rehabilitation/reintegration and recovery services adopting case management and inter-agency approaches | | | | |
| — | Extent of increase in the number of gender specific rehabilitation/reintegration and recovery programmes | | | | |
| — | Extent of increase in the number of community care and prison programmes, specifically targeted at drug users with co-morbidity, involving partnerships between both mental health and drug rehabilitation/reintegration and recovery services | | | | |
| — | Level and duration of abstentions from consumption of illicit and/or licit drugs by people leaving drug treatment | | | | |
| — | Availability of treatment options to meet needs of people who experience relapses to drug use and of ageing drug users | | | | |
| | 8.
a.
Scale up where applicable, availability, coverage and access to risk and harm reduction services e.g. needle and syringe exchange programmes, opioid substitution treatment, opioid overdose management programmes, to lessen the negative consequences of drug use and to prevent and to substantially reduce the number of direct and indirect drug-related deaths and infectious blood-borne diseases associated with drug use but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis in accordance with the WHO recommendation on the comprehensive package of health services for people who inject drugs b.
Better prevent drug related deaths according to national circumstances as for example in the case of opiates, by providing access to authorised pharmaceutical dosage forms of medicinal products containing naloxone specifically certified to treat opioid overdose symptoms by trained laypersons in the absence of medical professionals c.
Identify and overcome barriers in detection and access to treatment for HIV and hepatitis C among people who inject drugs, including prisoners and other vulnerable groups d.
Exchange of information and where applicable best practice on risk and harm reduction measures such as, needle and syringe exchange programmes, opioid substitution treatment, drug consumption rooms, naloxone programmes, peer-based interventions, outreach treatment programmes, hepatitis C treatment, pill testing, self-testing for HIV/AIDS, in accordance with national legislation | 8. | a.
Scale up where applicable, availability, coverage and access to risk and harm reduction services e.g. needle and syringe exchange programmes, opioid substitution treatment, opioid overdose management programmes, to lessen the negative consequences of drug use and to prevent and to substantially reduce the number of direct and indirect drug-related deaths and infectious blood-borne diseases associated with drug use but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis in accordance with the WHO recommendation on the comprehensive package of health services for people who inject drugs b.
Better prevent drug related deaths according to national circumstances as for example in the case of opiates, by providing access to authorised pharmaceutical dosage forms of medicinal products containing naloxone specifically certified to treat opioid overdose symptoms by trained laypersons in the absence of medical professionals c.
Identify and overcome barriers in detection and access to treatment for HIV and hepatitis C among people who inject drugs, including prisoners and other vulnerable groups d.
Exchange of information and where applicable best practice on risk and harm reduction measures such as, needle and syringe exchange programmes, opioid substitution treatment, drug consumption rooms, naloxone programmes, peer-based interventions, outreach treatment programmes, hepatitis C treatment, pill testing, self-testing for HIV/AIDS, in accordance with national legislation | a. | Scale up where applicable, availability, coverage and access to risk and harm reduction services e.g. needle and syringe exchange programmes, opioid substitution treatment, opioid overdose management programmes, to lessen the negative consequences of drug use and to prevent and to substantially reduce the number of direct and indirect drug-related deaths and infectious blood-borne diseases associated with drug use but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis in accordance with the WHO recommendation on the comprehensive package of health services for people who inject drugs |
| 8. | a.
Scale up where applicable, availability, coverage and access to risk and harm reduction services e.g. needle and syringe exchange programmes, opioid substitution treatment, opioid overdose management programmes, to lessen the negative consequences of drug use and to prevent and to substantially reduce the number of direct and indirect drug-related deaths and infectious blood-borne diseases associated with drug use but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis in accordance with the WHO recommendation on the comprehensive package of health services for people who inject drugs b.
Better prevent drug related deaths according to national circumstances as for example in the case of opiates, by providing access to authorised pharmaceutical dosage forms of medicinal products containing naloxone specifically certified to treat opioid overdose symptoms by trained laypersons in the absence of medical professionals c.
Identify and overcome barriers in detection and access to treatment for HIV and hepatitis C among people who inject drugs, including prisoners and other vulnerable groups d.
Exchange of information and where applicable best practice on risk and harm reduction measures such as, needle and syringe exchange programmes, opioid substitution treatment, drug consumption rooms, naloxone programmes, peer-based interventions, outreach treatment programmes, hepatitis C treatment, pill testing, self-testing for HIV/AIDS, in accordance with national legislation | a. | Scale up where applicable, availability, coverage and access to risk and harm reduction services e.g. needle and syringe exchange programmes, opioid substitution treatment, opioid overdose management programmes, to lessen the negative consequences of drug use and to prevent and to substantially reduce the number of direct and indirect drug-related deaths and infectious blood-borne diseases associated with drug use but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis in accordance with the WHO recommendation on the comprehensive package of health services for people who inject drugs | b. | Better prevent drug related deaths according to national circumstances as for example in the case of opiates, by providing access to authorised pharmaceutical dosage forms of medicinal products containing naloxone specifically certified to treat opioid overdose symptoms by trained laypersons in the absence of medical professionals |
| a. | Scale up where applicable, availability, coverage and access to risk and harm reduction services e.g. needle and syringe exchange programmes, opioid substitution treatment, opioid overdose management programmes, to lessen the negative consequences of drug use and to prevent and to substantially reduce the number of direct and indirect drug-related deaths and infectious blood-borne diseases associated with drug use but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis in accordance with the WHO recommendation on the comprehensive package of health services for people who inject drugs | | | | |
| b. | Better prevent drug related deaths according to national circumstances as for example in the case of opiates, by providing access to authorised pharmaceutical dosage forms of medicinal products containing naloxone specifically certified to treat opioid overdose symptoms by trained laypersons in the absence of medical professionals | | | | |
| c. | Identify and overcome barriers in detection and access to treatment for HIV and hepatitis C among people who inject drugs, including prisoners and other vulnerable groups | | | | |
| d. | Exchange of information and where applicable best practice on risk and harm reduction measures such as, needle and syringe exchange programmes, opioid substitution treatment, drug consumption rooms, naloxone programmes, peer-based interventions, outreach treatment programmes, hepatitis C treatment, pill testing, self-testing for HIV/AIDS, in accordance with national legislation | | | | |
| — | Over-arching indicators 2, 3, 4, 11 | | | | |
| — | Extent of increased availability of and access to evidence-based risk and harm reduction measures in MS where applicable | | | | |
| — | Overview of exchanges of best practices on risk and harm reduction measures | | | | |
| — | Number of MS reaching the WHO recommendation on the comprehensive package of health services for people who inject drugs:
—
Needle/Syringe programmes —
Opioid substitution treatment —
HIV testing and counselling —
HIV treatment and care —
Condom programmes —
Behavioural interventions —
Prevention and management of hepatitis, tuberculosis and mental health —
Sexual reproductive health interventions —
Naloxone training for laypersons as an irreplaceable prerequisite for safe take-home programmes | — | Needle/Syringe programmes | — | Opioid substitution treatment |
| — | Needle/Syringe programmes | | | | |
| — | Opioid substitution treatment | | | | |
| — | HIV testing and counselling | | | | |
| — | HIV treatment and care | | | | |
| — | Condom programmes | | | | |
| — | Behavioural interventions | | | | |
| — | Prevention and management of hepatitis, tuberculosis and mental health | | | | |
| — | Sexual reproductive health interventions | | | | |
| — | Naloxone training for laypersons as an irreplaceable prerequisite for safe take-home programmes | | | | |
| — | Coverage of opioid substitution treatment programmes among people with opioid dependence | | | | |
| — | The extent of availability, where applicable, of harm reduction services such as naloxone programmes, nightlife harm reduction measures and programmes targeting vulnerable communities/populations | | | | |
| — | Number of programmes facilitating the access of people who inject drugs into treatment for the hepatitis C virus (HCV) and people covered | | | | |
| — | Degree of implementation of ECDC/EMCDDA guidance on prevention and control of infectious diseases among people injecting drugs | | | | |
| | 9.
Scale up the development, availability and coverage of health care measures for drug users in prison and after release with the aim of achieving a quality of care equivalent to that provided in the community | 9. | Scale up the development, availability and coverage of health care measures for drug users in prison and after release with the aim of achieving a quality of care equivalent to that provided in the community | Ongoing | MS |
| 9. | Scale up the development, availability and coverage of health care measures for drug users in prison and after release with the aim of achieving a quality of care equivalent to that provided in the community | | | | |
| — | Over-arching indicator 10 | | | | |
| — | Availability of services for drug users in prisons (such as opioid substitution treatment and if applicable, naloxone programmes and needle and syringe exchange programmes in accordance with national legislation and prevention and management of HIV, Hepatitis B, Hepatitis C and TB) and the extent to which prison health care policies and practices incorporate care models comprising best practices in needs assessment and continuity of care for prisoners during imprisonment | | | | |
| — | Extent to which prison based services and community based services provide continuity of care for prisoners upon release with particular emphasis on avoiding drug overdoses | | | | |
| 3.
Embed coordinated, best practice and quality approaches in drug demand reduction | 3. | Embed coordinated, best practice and quality approaches in drug demand reduction | 10.
Implement the EU minimum quality standards adopted by the Council in 2015( 2 ) that help bridge the gap between science and practice, for:
a.
environmental, universal, selective and indicated prevention measures; b.
early detection and intervention measures; c.
risk and harm reduction measures; and d.
treatment, rehabilitation, social integration and recovery measures and monitor their implementation. | 10. | Implement the EU minimum quality standards adopted by the Council in 2015( 2 ) that help bridge the gap between science and practice, for:
a.
environmental, universal, selective and indicated prevention measures; b.
early detection and intervention measures; c.
risk and harm reduction measures; and d.
treatment, rehabilitation, social integration and recovery measures and monitor their implementation. |
| 3. | Embed coordinated, best practice and quality approaches in drug demand reduction | | | | |
| 10. | Implement the EU minimum quality standards adopted by the Council in 2015( 2 ) that help bridge the gap between science and practice, for:
a.
environmental, universal, selective and indicated prevention measures; b.
early detection and intervention measures; c.
risk and harm reduction measures; and d.
treatment, rehabilitation, social integration and recovery measures and monitor their implementation. | a. | environmental, universal, selective and indicated prevention measures; | b. | early detection and intervention measures; |
| a. | environmental, universal, selective and indicated prevention measures; | | | | |
| b. | early detection and intervention measures; | | | | |
| c. | risk and harm reduction measures; and | | | | |
| d. | treatment, rehabilitation, social integration and recovery measures | | | | |
| — | Evidence review of drug demand reduction measures and programmes implemented in accordance with the standards; | | | | |
| — | Number of specialist training programmes available for practitioners in drug demand reduction and/or estimated number of practitioners reached by specialist training programmes; | | | | |
| — | Involvement of civil society in the implementation of the standards, including in planning and introduction | | | | |
| — | Number of projects and programmes supported at EU level that promote the exchange of best practices in the implementation of these standards | | | | |
| — | Engagement in inter-ministerial cooperation to support implementation of these standards. | | | | |

2.   Drug supply reduction

Contribute to a measurable reduction of the availability and supply of illicit drugs in the EU

| Objective | Action | Timetable | Responsible party | Indicator(s) | Data collection/assessment mechanisms |
| ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------ | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| 4.
Enhance effective law enforcement coordination and cooperation within the EU to counter illicit drug activity, in coherence, as appropriate, with relevant actions determined through the EU policy cycle | 4. | Enhance effective law enforcement coordination and cooperation within the EU to counter illicit drug activity, in coherence, as appropriate, with relevant actions determined through the EU policy cycle | 11.
Utilise to best effect available intelligence and information sharing law enforcement instruments, channels and communication tools used to collate and analyse drug-related information | 11. | Utilise to best effect available intelligence and information sharing law enforcement instruments, channels and communication tools used to collate and analyse drug-related information |
| 4. | Enhance effective law enforcement coordination and cooperation within the EU to counter illicit drug activity, in coherence, as appropriate, with relevant actions determined through the EU policy cycle | | | | |
| 11. | Utilise to best effect available intelligence and information sharing law enforcement instruments, channels and communication tools used to collate and analyse drug-related information | | | | |
| — | Over-arching indicator 7, 15 | | | | |
| — | Extent of high impact intelligence led and targeted activities, of joint operations, joint investigation teams and cross border cooperation initiatives focusing on criminal organisations engaged in illicit drug activity | | | | |
| — | Increased use of drug-related information-sharing, analysis and expert systems of Europol or other law enforcement authorities | | | | |
| — | Results achieved from EMPACT projects and bilateral and multilateral initiatives | | | | |
| — | Number of drug-related cases referred to Eurojust and Europol, including qualitative, contextual information about the cases | | | | |
| | 12.
Identify and prioritise the most pressing threats associated with drug-related organised crime | 12. | Identify and prioritise the most pressing threats associated with drug-related organised crime | 2017 | Council
Council WP (COSI)
Europol
MS
COM |
| 12. | Identify and prioritise the most pressing threats associated with drug-related organised crime | | | | |
| — | EU Policy Cycle for organised and serious international crime for the period 2018-2021 in place | | | | |
| | 13.
Strengthen CEPOL's training for law enforcement officers in relation to illicit drug production, trafficking and financial crime, particularly training methods and techniques
a.
to address the use of new communication technologies in illicit drug production and trafficking; b.
to enhance asset confiscation; c.
to counter money laundering; d.
to detect and dismantle illicit clandestine laboratories and cannabis cultivation sites. | 13. | Strengthen CEPOL's training for law enforcement officers in relation to illicit drug production, trafficking and financial crime, particularly training methods and techniques
a.
to address the use of new communication technologies in illicit drug production and trafficking; b.
to enhance asset confiscation; c.
to counter money laundering; d.
to detect and dismantle illicit clandestine laboratories and cannabis cultivation sites. | a. | to address the use of new communication technologies in illicit drug production and trafficking; |
| 13. | Strengthen CEPOL's training for law enforcement officers in relation to illicit drug production, trafficking and financial crime, particularly training methods and techniques
a.
to address the use of new communication technologies in illicit drug production and trafficking; b.
to enhance asset confiscation; c.
to counter money laundering; d.
to detect and dismantle illicit clandestine laboratories and cannabis cultivation sites. | a. | to address the use of new communication technologies in illicit drug production and trafficking; | b. | to enhance asset confiscation; |
| a. | to address the use of new communication technologies in illicit drug production and trafficking; | | | | |
| b. | to enhance asset confiscation; | | | | |
| c. | to counter money laundering; | | | | |
| d. | to detect and dismantle illicit clandestine laboratories and cannabis cultivation sites. | | | | |
| — | Training needs assessment carried out regularly | | | | |
| — | Availability and uptake of relevant training courses | | | | |
| — | Number of law enforcement officers trained and effectively deployed as a result | | | | |
| | 14.
Improve counter-narcotic activities through strengthening and monitoring the effectiveness of regional information-sharing platforms and regional security-sharing platforms with the aim of disrupting and suppressing emerging threats from changing drug trafficking routes | 14. | Improve counter-narcotic activities through strengthening and monitoring the effectiveness of regional information-sharing platforms and regional security-sharing platforms with the aim of disrupting and suppressing emerging threats from changing drug trafficking routes | Ongoing | COM
MS
Europol
Council WP (COSI)
Regional Information-Sharing Platforms
Regional Security-Sharing Platforms |
| 14. | Improve counter-narcotic activities through strengthening and monitoring the effectiveness of regional information-sharing platforms and regional security-sharing platforms with the aim of disrupting and suppressing emerging threats from changing drug trafficking routes | | | | |
| — | Over-arching indicator 7 | | | | |
| — | Number of intelligence-led activities leading to the disruption and suppression of drug trafficking routes | | | | |
| — | Level of information sharing through effective activity of the liaison officer network | | | | |
| | 15.
Strengthen actions to prevent the diversion of drug precursors and pre-precursors for use in the illicit manufacture of drugs | 15. | Strengthen actions to prevent the diversion of drug precursors and pre-precursors for use in the illicit manufacture of drugs | Ongoing | MS
Europol
COM
Council WP (CUG
COSI) |
| 15. | Strengthen actions to prevent the diversion of drug precursors and pre-precursors for use in the illicit manufacture of drugs | | | | |
| — | Number of cases and quantity of stopped or seized shipments of precursors intended for illicit use | | | | |
| — | Results achieved from EMPACT projects | | | | |
| — | Use of Pre-Export Notification (PEN) Online System and increased use of the Precursors Incident Communication System (PICS) | | | | |
| — | Number of joint follow-up meetings and other activities linked to the prevention of the diversion of precursors and pre-precursors | | | | |
| | 16.
Counter cross-border drug trafficking, including through container and parcel shipments, and improve border security notably at EU seaports, airports and land border crossing points through intensified efforts, including information and intelligence sharing, by relevant law enforcement authorities | 16. | Counter cross-border drug trafficking, including through container and parcel shipments, and improve border security notably at EU seaports, airports and land border crossing points through intensified efforts, including information and intelligence sharing, by relevant law enforcement authorities | Ongoing | MS
Europol
Council WP
(CCWP
COSI) |
| 16. | Counter cross-border drug trafficking, including through container and parcel shipments, and improve border security notably at EU seaports, airports and land border crossing points through intensified efforts, including information and intelligence sharing, by relevant law enforcement authorities | | | | |
| — | Number of multi-disciplinary/multi-agency joint operations and cross border cooperation initiatives | | | | |
| — | Intensified information exchange for example such as Memoranda of Understanding (MOU) agreed between law enforcement authorities and relevant bodies such as airlines, air express couriers, shipping companies, harbour authorities and chemical companies | | | | |
| — | Results achieved from EMPACT projects | | | | |
| — | Improved intelligence and information sharing on cross-border drug trafficking utilising, inter alia, available border surveillance systems | | | | |
| — | Implementation of the EU Passenger Name Record (PNR) directive | | | | |
| | 17.
Implement the key indicators on drug supply reduction adopted by the Council in 2013( 4 ) | 17. | Implement the key indicators on drug supply reduction adopted by the Council in 2013( 4 ) | 2017-2020 | COM
MS
Council
Council WP (HDG)
EMCDDA
Europol |
| 17. | Implement the key indicators on drug supply reduction adopted by the Council in 2013( 4 ) | | | | |
| — | number and quantity of drug seizures | | | | |
| — | purity and content of drugs | | | | |
| — | drug prices | | | | |
| — | drug production facilities dismantled | | | | |
| — | drug law offences | | | | |
| — | drug availability in population surveys | | | | |
| — | market size estimates | | | | |
| 5.
Enhance effective judicial cooperation and legislation within the EU | 5. | Enhance effective judicial cooperation and legislation within the EU | 18.
Strengthen EU judicial cooperation in targeting cross-border drug trafficking, money laundering, and in the confiscation of the proceeds of drug-related organised crime | 18. | Strengthen EU judicial cooperation in targeting cross-border drug trafficking, money laundering, and in the confiscation of the proceeds of drug-related organised crime |
| 5. | Enhance effective judicial cooperation and legislation within the EU | | | | |
| 18. | Strengthen EU judicial cooperation in targeting cross-border drug trafficking, money laundering, and in the confiscation of the proceeds of drug-related organised crime | | | | |
| — | Timely implementation of agreed EU measures and legislation on (a) confiscation and recovery of criminal assets( 5 ); (b) money laundering( 6 ); (c) approximation of drug trafficking offences and sanctions across the EU( 7 ) | | | | |
| — | Increased number of financial investigations and confiscations in relation to the proceeds of drug-related organised crime through EU law enforcement authorities and judicial cooperation | | | | |
| — | Timely and effective responses to mutual legal assistance requests and European Arrest Warrants in relation to illicit drug trafficking | | | | |
| | 19.
Adopt and implement new EU legislative measures to address the emergence, use and rapid spread of new psychoactive substances | 19. | Adopt and implement new EU legislative measures to address the emergence, use and rapid spread of new psychoactive substances | 2017-2020 | COM
Council
Council WP (HDG)
MS
EMCDDA
Europol
EUROJUST |
| 19. | Adopt and implement new EU legislative measures to address the emergence, use and rapid spread of new psychoactive substances | | | | |
| — | EU legislation in place | | | | |
| — | Implementation of EU legislation in MS | | | | |
| — | Updating of EU guidelines for the information exchange and risk assessment procedures | | | | |
| — | Monitor the effects of new legislative measures with a special focus on the replacement-effect in the illegal drug market | | | | |
| | 20.
Implement EU legislation on drug precursors to prevent their diversion without disrupting lawful trade | 20. | Implement EU legislation on drug precursors to prevent their diversion without disrupting lawful trade | Ongoing | Council
COM
MS |
| 20. | Implement EU legislation on drug precursors to prevent their diversion without disrupting lawful trade | | | | |
| — | Information on cases and quantity of stopped or seized shipments of precursors intended for illicit use | | | | |
| — | Results achieved from EMPACT projects | | | | |
| — | Use of Pre-Export Notification (PEN) Online System and increased use of the Precursors Incident Communication System (PICS) | | | | |
| — | Number of joint follow up meetings and other activities linked to the prevention of the diversion of precursors and pre-precursors. | | | | |
| | 21.
Address the use of certain pharmacologically active substances (as defined in Directive 2011/62/EU) as cutting agents for illicit drugs | 21. | Address the use of certain pharmacologically active substances (as defined in Directive 2011/62/EU) as cutting agents for illicit drugs | Ongoing | MS
COM
EMA
Europol |
| 21. | Address the use of certain pharmacologically active substances (as defined in Directive 2011/62/EU) as cutting agents for illicit drugs | | | | |
| — | Information on seizures of active substances used as cutting agents for illicit drugs | | | | |
| — | Timely implementation of new EU legislative requirements aimed at securing the supply chain for active substances under Directive 2011/62/EU, the Falsified Medicines Directive | | | | |
| | 22.
Members States to provide and apply, where appropriate and in accordance with their legal frameworks, alternatives to coercive sanctions for drug using offenders, such as:
a.
Education b.
(Suspension of sentence with) treatment c.
Suspension of investigation or prosecution d.
Rehabilitation and recovery e.
Aftercare and social reintegration | 22. | Members States to provide and apply, where appropriate and in accordance with their legal frameworks, alternatives to coercive sanctions for drug using offenders, such as:
a.
Education b.
(Suspension of sentence with) treatment c.
Suspension of investigation or prosecution d.
Rehabilitation and recovery e.
Aftercare and social reintegration | a. | Education |
| 22. | Members States to provide and apply, where appropriate and in accordance with their legal frameworks, alternatives to coercive sanctions for drug using offenders, such as:
a.
Education b.
(Suspension of sentence with) treatment c.
Suspension of investigation or prosecution d.
Rehabilitation and recovery e.
Aftercare and social reintegration | a. | Education | b. | (Suspension of sentence with) treatment |
| a. | Education | | | | |
| b. | (Suspension of sentence with) treatment | | | | |
| c. | Suspension of investigation or prosecution | | | | |
| d. | Rehabilitation and recovery | | | | |
| e. | Aftercare and social reintegration | | | | |
| — | Increased availability and implementation of alternatives to coercive sanctions for drug-using offenders in the areas of education, treatment, rehabilitation, aftercare and social integration. | | | | |
| — | Increased monitoring, implementation and evaluation of alternatives to coercive sanctions | | | | |
| — | Type and number of alternatives to coercive sanctions provided for and implemented by MS | | | | |
| — | Information on the effectiveness of the use of alternatives to coercive sanctions | | | | |
| 6.
Respond effectively to current and emerging trends in illicit drug activity | 6. | Respond effectively to current and emerging trends in illicit drug activity | 23.
Identify strategic responses to address the role of new information communication technologies (ICT) and the hosting of associated websites, in the production, marketing, purchasing and distribution of illicit drugs and new psychoactive substances at national and EU level. | 23. | Identify strategic responses to address the role of new information communication technologies (ICT) and the hosting of associated websites, in the production, marketing, purchasing and distribution of illicit drugs and new psychoactive substances at national and EU level. |
| 6. | Respond effectively to current and emerging trends in illicit drug activity | | | | |
| 23. | Identify strategic responses to address the role of new information communication technologies (ICT) and the hosting of associated websites, in the production, marketing, purchasing and distribution of illicit drugs and new psychoactive substances at national and EU level. | | | | |
| — | Results achieved from law enforcement actions targeting drug-related crime via the internet | | | | |
| — | Increased number of joint operations and cross border cooperation initiatives | | | | |
| — | Number and impact of funded research projects and tools developed to support law enforcement | | | | |
| — | Number of agreements/discussions with relevant industry partners | | | | |
| — | Setting up of a glossary of terms | | | | |
| — | Setting up of an inventory of monitoring tools | | | | |
| — | Numbers of training sessions for relevant stakeholders | | | | |
| — | Number of meetings with international partners in which the action was discussed | | | | |

3.   Coordination

Member States and EU to effectively coordinate drugs policy

| Objective | Action | Timetable | Responsible party | Indicator(s) | Data collection/assessment mechanisms |
| -------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| 7.
Ensure effective EU coordination in the drugs field | 7. | Ensure effective EU coordination in the drugs field | 24.
Enhance information-sharing between the HDG and other relevant Council Working Parties and in particular COSI to enhance coordination as regards the drug supply reduction pillar
Enhance information sharing between the HDG and other relevant geographical and thematic Council Working Parties including such as COSI, COAFR, COASI, COEST, COLAC, COTRA, COWEB, CONUN, COHOM, CCWP, COSCE, CUG and DROIPEN | 24. | Enhance information-sharing between the HDG and other relevant Council Working Parties and in particular COSI to enhance coordination as regards the drug supply reduction pillar
Enhance information sharing between the HDG and other relevant geographical and thematic Council Working Parties including such as COSI, COAFR, COASI, COEST, COLAC, COTRA, COWEB, CONUN, COHOM, CCWP, COSCE, CUG and DROIPEN |
| 7. | Ensure effective EU coordination in the drugs field | | | | |
| 24. | Enhance information-sharing between the HDG and other relevant Council Working Parties and in particular COSI to enhance coordination as regards the drug supply reduction pillar
Enhance information sharing between the HDG and other relevant geographical and thematic Council Working Parties including such as COSI, COAFR, COASI, COEST, COLAC, COTRA, COWEB, CONUN, COHOM, CCWP, COSCE, CUG and DROIPEN | | | | |
| — | Extent to which the EU Drugs Strategy/and Action Plan are taken into account in the Programmes of other Council Working Parties such as COSI, COAFR, COASI, COEST, COLAC, COTRA, COWEB, CONUN, COHOM, CCWP, COSCE, CUG and DROIPEN. | | | | |
| — | Regular information point on the HDG agenda on (1) activities linked to drug-related priorities of the EU Policy Cycle (based on EMPACT reporting, once per Presidency); and (2) relevant activities of other Council Working Parties, in the presence of other relevant Working Party Chairs, where appropriate | | | | |
| | 25.
Each Presidency may convene meetings of the National Drugs Coordinators, and of other groupings as appropriate, to consider emerging trends, effective interventions and other policy developments of added value to the EU Drugs Strategy and to MS | 25. | Each Presidency may convene meetings of the National Drugs Coordinators, and of other groupings as appropriate, to consider emerging trends, effective interventions and other policy developments of added value to the EU Drugs Strategy and to MS | Biannually | PRES
MS |
| 25. | Each Presidency may convene meetings of the National Drugs Coordinators, and of other groupings as appropriate, to consider emerging trends, effective interventions and other policy developments of added value to the EU Drugs Strategy and to MS | | | | |
| — | Extent to which National Drug Coordinators' meeting agenda reflects developments, trends and new insights in policy responses and provides for improved communication and information exchange | | | | |
| | 26.
The HDG will facilitate (a) monitoring of the implementation of the Action Plan through thematic debates; and (b) an annual dialogue on the state of the drugs phenomenon in Europe | 26. | The HDG will facilitate (a) monitoring of the implementation of the Action Plan through thematic debates; and (b) an annual dialogue on the state of the drugs phenomenon in Europe | (a)
Ongoing (b)
Annually | (a) |
| 26. | The HDG will facilitate (a) monitoring of the implementation of the Action Plan through thematic debates; and (b) an annual dialogue on the state of the drugs phenomenon in Europe | | | | |
| (a) | Ongoing | | | | |
| (b) | Annually | | | | |
| — | Extent of implementation of the Action Plan | | | | |
| — | Number of actions from the Action Plan addressed in thematic debates in the HDG | | | | |
| — | Timeliness of dialogue at the HDG on latest drug-related trends and data | | | | |
| | 27.
Ensure consistency and continuity of MS and EU actions across Presidencies to strengthen the integrated, balanced and evidence-based approach to drugs in the EU | 27. | Ensure consistency and continuity of MS and EU actions across Presidencies to strengthen the integrated, balanced and evidence-based approach to drugs in the EU | Ongoing | PRES
PRES Trio
MS
COM
Council WP (HDG)
EMCDDA
Europol |
| 27. | Ensure consistency and continuity of MS and EU actions across Presidencies to strengthen the integrated, balanced and evidence-based approach to drugs in the EU | | | | |
| — | Extent of consistency and continuity of actions across Presidencies | | | | |
| — | Advancement in implementation of EU Drugs Strategy priorities across Presidencies | | | | |
| | 28.
Ensure coordination of EU drugs policies and responses, to support international cooperation between the EU, third countries and international organisations | 28. | Ensure coordination of EU drugs policies and responses, to support international cooperation between the EU, third countries and international organisations | Ongoing | EEAS
COM
Council WP (HDG)
MS |
| 28. | Ensure coordination of EU drugs policies and responses, to support international cooperation between the EU, third countries and international organisations | | | | |
| — | Level of consistency and coherence in the objectives, expected results and measures foreseen in EU actions on drugs | | | | |
| — | Inclusion of drug-related priorities in strategies of relevant EU bodies | | | | |
| — | Intensified cooperation between the HDG and the geographical/regional and thematic Council Working Parties, including COSI, COAFR, COASI, COEST, COLAT, COTRA, COWEB, CONUN and COHOM, CCWP, COSCE, CUG and DROIPEN | | | | |
| — | Number of reports by Dublin Group | | | | |
| | 29.
a.
Achieve a coordinated and appropriate level of resources at EU level and Member State level to fulfil the priorities of the EU Drugs Strategy b.
Strengthen the cooperation to tackle the rising trend of stimulant addiction, in particular methamphetamine, between relevant government bodies and the NGO sector, focusing on creating and sharing best practices in preventing the spread from local epidemics, including demand and supply reduction efforts, and sharing information on the prevention of misuse of medicinal products for methamphetamine production. | 29. | a.
Achieve a coordinated and appropriate level of resources at EU level and Member State level to fulfil the priorities of the EU Drugs Strategy b.
Strengthen the cooperation to tackle the rising trend of stimulant addiction, in particular methamphetamine, between relevant government bodies and the NGO sector, focusing on creating and sharing best practices in preventing the spread from local epidemics, including demand and supply reduction efforts, and sharing information on the prevention of misuse of medicinal products for methamphetamine production. | a. | Achieve a coordinated and appropriate level of resources at EU level and Member State level to fulfil the priorities of the EU Drugs Strategy |
| 29. | a.
Achieve a coordinated and appropriate level of resources at EU level and Member State level to fulfil the priorities of the EU Drugs Strategy b.
Strengthen the cooperation to tackle the rising trend of stimulant addiction, in particular methamphetamine, between relevant government bodies and the NGO sector, focusing on creating and sharing best practices in preventing the spread from local epidemics, including demand and supply reduction efforts, and sharing information on the prevention of misuse of medicinal products for methamphetamine production. | a. | Achieve a coordinated and appropriate level of resources at EU level and Member State level to fulfil the priorities of the EU Drugs Strategy | b. | Strengthen the cooperation to tackle the rising trend of stimulant addiction, in particular methamphetamine, between relevant government bodies and the NGO sector, focusing on creating and sharing best practices in preventing the spread from local epidemics, including demand and supply reduction efforts, and sharing information on the prevention of misuse of medicinal products for methamphetamine production. |
| a. | Achieve a coordinated and appropriate level of resources at EU level and Member State level to fulfil the priorities of the EU Drugs Strategy | | | | |
| b. | Strengthen the cooperation to tackle the rising trend of stimulant addiction, in particular methamphetamine, between relevant government bodies and the NGO sector, focusing on creating and sharing best practices in preventing the spread from local epidemics, including demand and supply reduction efforts, and sharing information on the prevention of misuse of medicinal products for methamphetamine production. | | | | |
| — | Over-arching indicator 14 | | | | |
| — | Amount of funding at EU level, and where appropriate, MS level | | | | |
| — | Extent of coordination on drugs-related financial programmes across Council Working Parties and COM | | | | |
| — | Level of networking between professionals from both statutory and non-statutory sector | | | | |
| — | Availability of accessible interventions | | | | |
| — | Number of developed interventions | | | | |
| 8.
Ensure effective coordination of drug-related policy at national level | 8. | Ensure effective coordination of drug-related policy at national level | 30.
Coordinate actions on drugs policy between Government Departments/Ministries and relevant agencies at MS level and ensure appropriate multi-disciplinary representation on, or input to, HDG delegations | 30. | Coordinate actions on drugs policy between Government Departments/Ministries and relevant agencies at MS level and ensure appropriate multi-disciplinary representation on, or input to, HDG delegations |
| 8. | Ensure effective coordination of drug-related policy at national level | | | | |
| 30. | Coordinate actions on drugs policy between Government Departments/Ministries and relevant agencies at MS level and ensure appropriate multi-disciplinary representation on, or input to, HDG delegations | | | | |
| — | Over-arching indicator 14 | | | | |
| — | Effectiveness of a horizontal drug policy coordination mechanism at MS level | | | | |
| — | Number of cross-cutting actions in drug demand and supply reduction at Member State level | | | | |
| 9.
Ensure the participation of civil society in drugs policy | 9. | Ensure the participation of civil society in drugs policy | 31.
Promote and strengthen dialogue with, and involvement of, civil society and the scientific community in the formulation, implementation, monitoring and evaluation of drug policies at MS and EU levels | 31. | Promote and strengthen dialogue with, and involvement of, civil society and the scientific community in the formulation, implementation, monitoring and evaluation of drug policies at MS and EU levels |
| 9. | Ensure the participation of civil society in drugs policy | | | | |
| 31. | Promote and strengthen dialogue with, and involvement of, civil society and the scientific community in the formulation, implementation, monitoring and evaluation of drug policies at MS and EU levels | | | | |
| — | Timely dialogues between EU Civil Society Forum on Drugs and the HDG during each Presidency period | | | | |
| — | Engagement of EU Civil Society Forum in reviewing implementation of the EU Drug Action Plan | | | | |
| — | Level of involvement of civil society and the scientific community in MS and EU drug policy formulation, implementation, monitoring and evaluation | | | | |
| — | Timely dialogue between the scientific community (natural and social sciences, including neuroscience and behavioural research) and the HDG | | | | |

4.   International cooperation

Strengthen dialogue and cooperation between the EU and third countries and international organisations on drugs issues in a comprehensive and balanced manner

| Objective | Action | Timetable | Responsible party | Indicator(s) | Data collection/assessment mechanisms |
| -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------ | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| 10.
Integrate the EU Drugs Strategy within the EU's overall foreign policy framework as part of a comprehensive approach that makes full use of the variety of policies and diplomatic, political and financial instruments at the EU's disposal in a coherent and coordinated manner | 10. | Integrate the EU Drugs Strategy within the EU's overall foreign policy framework as part of a comprehensive approach that makes full use of the variety of policies and diplomatic, political and financial instruments at the EU's disposal in a coherent and coordinated manner | 32.
Ensure policy coherence between the internal and external aspects of the EU drug policies and fully integrate drug issues within the political dialogues and framework agreements between the EU and its partners and in the EU advocacy on global issues or challenges | 32. | Ensure policy coherence between the internal and external aspects of the EU drug policies and fully integrate drug issues within the political dialogues and framework agreements between the EU and its partners and in the EU advocacy on global issues or challenges |
| 10. | Integrate the EU Drugs Strategy within the EU's overall foreign policy framework as part of a comprehensive approach that makes full use of the variety of policies and diplomatic, political and financial instruments at the EU's disposal in a coherent and coordinated manner | | | | |
| 32. | Ensure policy coherence between the internal and external aspects of the EU drug policies and fully integrate drug issues within the political dialogues and framework agreements between the EU and its partners and in the EU advocacy on global issues or challenges | | | | |
| — | Over-arching indicator 13 | | | | |
| — | Drug policy priorities increasingly reflected in EU's external policies and actions | | | | |
| — | Inclusion of drug-related priorities in EU strategies with third countries and regions | | | | |
| — | Number of agreements, strategy papers, action plans in place | | | | |
| | 33.
Ensure that the policy priorities and the balance between demand and supply reduction are well reflected in policy options and in the programming, implementation and monitoring of external assistance, particularly in source and transit countries, through projects involving:
a.
development of integrated, balanced and evidence-based drug policies; b.
supply reduction;
the prevention of the diversion of drug precursors and pre-precursors; c.
drug demand reduction; and d.
alternative development measures | 33. | Ensure that the policy priorities and the balance between demand and supply reduction are well reflected in policy options and in the programming, implementation and monitoring of external assistance, particularly in source and transit countries, through projects involving:
a.
development of integrated, balanced and evidence-based drug policies; b.
supply reduction;
the prevention of the diversion of drug precursors and pre-precursors; c.
drug demand reduction; and d.
alternative development measures | a. | development of integrated, balanced and evidence-based drug policies; |
| 33. | Ensure that the policy priorities and the balance between demand and supply reduction are well reflected in policy options and in the programming, implementation and monitoring of external assistance, particularly in source and transit countries, through projects involving:
a.
development of integrated, balanced and evidence-based drug policies; b.
supply reduction;
the prevention of the diversion of drug precursors and pre-precursors; c.
drug demand reduction; and d.
alternative development measures | a. | development of integrated, balanced and evidence-based drug policies; | b. | supply reduction;
the prevention of the diversion of drug precursors and pre-precursors; |
| a. | development of integrated, balanced and evidence-based drug policies; | | | | |
| b. | supply reduction;
the prevention of the diversion of drug precursors and pre-precursors; | | | | |
| c. | drug demand reduction; and | | | | |
| d. | alternative development measures | | | | |
| — | Extent to which EU's Drug policy priorities, especially the balance between demand and supply reduction, are reflected in funded priorities and projects | | | | |
| — | Level of implementation of coordinated actions in action plans between the EU and third countries and regions | | | | |
| — | Number of third country national strategies and action plans that incorporate integrated drug policies | | | | |
| | 34.
Improve capacity and strengthen the role of EU Delegations to enable them to proactively engage on drug policy issues and effectively report back on the local situation on drugs | 34. | Improve capacity and strengthen the role of EU Delegations to enable them to proactively engage on drug policy issues and effectively report back on the local situation on drugs | 2017-2020 | EEAS
COM
MS |
| 34. | Improve capacity and strengthen the role of EU Delegations to enable them to proactively engage on drug policy issues and effectively report back on the local situation on drugs | | | | |
| — | Relevant expertise, training and policy guidance provided to EU Delegations | | | | |
| — | Regional networking among EU Delegations on drug issues enhanced | | | | |
| — | Coordination with MS enhanced | | | | |
| | 35.
Promote and implement the EU approach to alternative development (consistent with the EU Drug Strategy 2013-2020; the EU Approach to Alternative Development and the United Nations Guiding Principles on Alternative Development 2013) in cooperation with third countries, taking into account human rights, human security, gender aspects and specific framework conditions, including:
a.
incorporating alternative development into the broader agenda of Member States, encouraging third countries that wish to do so to integrate alternative development into their national strategies; b.
contributing to initiatives that aim to reduce poverty, conflict and vulnerability by supporting sustainable, legal and gender sensitive livelihoods for people who were previously, or are currently, involved in illicit drug crop cultivation c.
providing an appropriate level of EU and MS funding and expertise to further strengthen and support non-EU countries' efforts in addressing and preventing illicit drug crop cultivation, through rural development measures and strengthening the rule of law in order to deal with the challenges of poverty reduction, public health, safety and security | 35. | Promote and implement the EU approach to alternative development (consistent with the EU Drug Strategy 2013-2020; the EU Approach to Alternative Development and the United Nations Guiding Principles on Alternative Development 2013) in cooperation with third countries, taking into account human rights, human security, gender aspects and specific framework conditions, including:
a.
incorporating alternative development into the broader agenda of Member States, encouraging third countries that wish to do so to integrate alternative development into their national strategies; b.
contributing to initiatives that aim to reduce poverty, conflict and vulnerability by supporting sustainable, legal and gender sensitive livelihoods for people who were previously, or are currently, involved in illicit drug crop cultivation c.
providing an appropriate level of EU and MS funding and expertise to further strengthen and support non-EU countries' efforts in addressing and preventing illicit drug crop cultivation, through rural development measures and strengthening the rule of law in order to deal with the challenges of poverty reduction, public health, safety and security | a. | incorporating alternative development into the broader agenda of Member States, encouraging third countries that wish to do so to integrate alternative development into their national strategies; |
| 35. | Promote and implement the EU approach to alternative development (consistent with the EU Drug Strategy 2013-2020; the EU Approach to Alternative Development and the United Nations Guiding Principles on Alternative Development 2013) in cooperation with third countries, taking into account human rights, human security, gender aspects and specific framework conditions, including:
a.
incorporating alternative development into the broader agenda of Member States, encouraging third countries that wish to do so to integrate alternative development into their national strategies; b.
contributing to initiatives that aim to reduce poverty, conflict and vulnerability by supporting sustainable, legal and gender sensitive livelihoods for people who were previously, or are currently, involved in illicit drug crop cultivation c.
providing an appropriate level of EU and MS funding and expertise to further strengthen and support non-EU countries' efforts in addressing and preventing illicit drug crop cultivation, through rural development measures and strengthening the rule of law in order to deal with the challenges of poverty reduction, public health, safety and security | a. | incorporating alternative development into the broader agenda of Member States, encouraging third countries that wish to do so to integrate alternative development into their national strategies; | b. | contributing to initiatives that aim to reduce poverty, conflict and vulnerability by supporting sustainable, legal and gender sensitive livelihoods for people who were previously, or are currently, involved in illicit drug crop cultivation |
| a. | incorporating alternative development into the broader agenda of Member States, encouraging third countries that wish to do so to integrate alternative development into their national strategies; | | | | |
| b. | contributing to initiatives that aim to reduce poverty, conflict and vulnerability by supporting sustainable, legal and gender sensitive livelihoods for people who were previously, or are currently, involved in illicit drug crop cultivation | | | | |
| c. | providing an appropriate level of EU and MS funding and expertise to further strengthen and support non-EU countries' efforts in addressing and preventing illicit drug crop cultivation, through rural development measures and strengthening the rule of law in order to deal with the challenges of poverty reduction, public health, safety and security | | | | |
| — | Number of third country national policies, strategies and action plans that incorporate:
—
integrated approaches to the problem of illicit drug crop cultivation and —
effectively organised alternative development initiatives | — | integrated approaches to the problem of illicit drug crop cultivation and | — | effectively organised alternative development initiatives |
| — | integrated approaches to the problem of illicit drug crop cultivation and | | | | |
| — | effectively organised alternative development initiatives | | | | |
| — | Number of evaluated projects that demonstrate positive outcomes relating to sustainable, legal and gender sensitive livelihoods | | | | |
| — | Improvements in human development indicators | | | | |
| — | Number of rural development projects and programmes, funded by the EU and MS in regions where illicit drug crop cultivation is taking place, or in regions at risk of illicit drug crop cultivation | | | | |
| — | Reported local decrease in illicit drug crop cultivation in the long-term | | | | |
| | 36.
Support third countries, including civil society in those countries, to develop and implement risk and harm reduction initiatives particularly where there is a growing threat of transmission of drug-related blood-borne viruses associated with drug use including but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis | 36. | Support third countries, including civil society in those countries, to develop and implement risk and harm reduction initiatives particularly where there is a growing threat of transmission of drug-related blood-borne viruses associated with drug use including but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis | Ongoing | MS
COM
EEAS |
| 36. | Support third countries, including civil society in those countries, to develop and implement risk and harm reduction initiatives particularly where there is a growing threat of transmission of drug-related blood-borne viruses associated with drug use including but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis | | | | |
| — | Number and quality of risk and harm reduction initiatives developed | | | | |
| — | Prevalence of drug-related deaths in third countries and drug-related blood-borne viruses including but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis | | | | |
| | 37.
Support third countries to tackle drug-related organised crime, including drug trafficking, by:
a.
intelligence-sharing and the exchange of best practices; b.
strengthening counter-narcotics capacity and developing expertise of source and transit countries; c.
working with international partners to tackle the enablers of drug trafficking such as corruption, weak institutions, poor governance and lack of financial regulatory controls; d.
strengthening cooperation in the field of asset identification and recovery, in particular through the creation of dedicated national platforms; and e.
intensifying regional and intra-regional cooperation f.
incorporating rule-of-law and international human rights standards and principles in drug-related law enforcement measures | 37. | Support third countries to tackle drug-related organised crime, including drug trafficking, by:
a.
intelligence-sharing and the exchange of best practices; b.
strengthening counter-narcotics capacity and developing expertise of source and transit countries; c.
working with international partners to tackle the enablers of drug trafficking such as corruption, weak institutions, poor governance and lack of financial regulatory controls; d.
strengthening cooperation in the field of asset identification and recovery, in particular through the creation of dedicated national platforms; and e.
intensifying regional and intra-regional cooperation f.
incorporating rule-of-law and international human rights standards and principles in drug-related law enforcement measures | a. | intelligence-sharing and the exchange of best practices; |
| 37. | Support third countries to tackle drug-related organised crime, including drug trafficking, by:
a.
intelligence-sharing and the exchange of best practices; b.
strengthening counter-narcotics capacity and developing expertise of source and transit countries; c.
working with international partners to tackle the enablers of drug trafficking such as corruption, weak institutions, poor governance and lack of financial regulatory controls; d.
strengthening cooperation in the field of asset identification and recovery, in particular through the creation of dedicated national platforms; and e.
intensifying regional and intra-regional cooperation f.
incorporating rule-of-law and international human rights standards and principles in drug-related law enforcement measures | a. | intelligence-sharing and the exchange of best practices; | b. | strengthening counter-narcotics capacity and developing expertise of source and transit countries; |
| a. | intelligence-sharing and the exchange of best practices; | | | | |
| b. | strengthening counter-narcotics capacity and developing expertise of source and transit countries; | | | | |
| c. | working with international partners to tackle the enablers of drug trafficking such as corruption, weak institutions, poor governance and lack of financial regulatory controls; | | | | |
| d. | strengthening cooperation in the field of asset identification and recovery, in particular through the creation of dedicated national platforms; and | | | | |
| e. | intensifying regional and intra-regional cooperation | | | | |
| f. | incorporating rule-of-law and international human rights standards and principles in drug-related law enforcement measures | | | | |
| — | Number and effectiveness of projects and programmes by the EU and the MS in non-EU countries | | | | |
| — | Sustained reduction in drug trafficking | | | | |
| | 38.
a.
Reinforce cooperation and/or conduct dialogue with partners, including:
—
Acceding countries, candidate countries and potential candidates —
European Neighbourhood Policy countries —
United States of America —
Russian Federation —
Other countries or regions of priority notably:
—
Afghanistan, Pakistan and Iran —
Central Asian Republics —
China —
Latin American and the Caribbean (CELAC) —
Africa, in particular West Africa —
Other countries depending on national and international developments b.
Explore possibilities for engagement (such as bilateral dialogues, joint projects) with other non-EU countries on serious drug-related issues | 38. | a.
Reinforce cooperation and/or conduct dialogue with partners, including:
—
Acceding countries, candidate countries and potential candidates —
European Neighbourhood Policy countries —
United States of America —
Russian Federation —
Other countries or regions of priority notably:
—
Afghanistan, Pakistan and Iran —
Central Asian Republics —
China —
Latin American and the Caribbean (CELAC) —
Africa, in particular West Africa —
Other countries depending on national and international developments b.
Explore possibilities for engagement (such as bilateral dialogues, joint projects) with other non-EU countries on serious drug-related issues | a. | Reinforce cooperation and/or conduct dialogue with partners, including:
—
Acceding countries, candidate countries and potential candidates —
European Neighbourhood Policy countries —
United States of America —
Russian Federation —
Other countries or regions of priority notably:
—
Afghanistan, Pakistan and Iran —
Central Asian Republics —
China —
Latin American and the Caribbean (CELAC) —
Africa, in particular West Africa —
Other countries depending on national and international developments |
| 38. | a.
Reinforce cooperation and/or conduct dialogue with partners, including:
—
Acceding countries, candidate countries and potential candidates —
European Neighbourhood Policy countries —
United States of America —
Russian Federation —
Other countries or regions of priority notably:
—
Afghanistan, Pakistan and Iran —
Central Asian Republics —
China —
Latin American and the Caribbean (CELAC) —
Africa, in particular West Africa —
Other countries depending on national and international developments b.
Explore possibilities for engagement (such as bilateral dialogues, joint projects) with other non-EU countries on serious drug-related issues | a. | Reinforce cooperation and/or conduct dialogue with partners, including:
—
Acceding countries, candidate countries and potential candidates —
European Neighbourhood Policy countries —
United States of America —
Russian Federation —
Other countries or regions of priority notably:
—
Afghanistan, Pakistan and Iran —
Central Asian Republics —
China —
Latin American and the Caribbean (CELAC) —
Africa, in particular West Africa —
Other countries depending on national and international developments | — | Acceding countries, candidate countries and potential candidates |
| a. | Reinforce cooperation and/or conduct dialogue with partners, including:
—
Acceding countries, candidate countries and potential candidates —
European Neighbourhood Policy countries —
United States of America —
Russian Federation —
Other countries or regions of priority notably:
—
Afghanistan, Pakistan and Iran —
Central Asian Republics —
China —
Latin American and the Caribbean (CELAC) —
Africa, in particular West Africa —
Other countries depending on national and international developments | — | Acceding countries, candidate countries and potential candidates | — | European Neighbourhood Policy countries |
| — | Acceding countries, candidate countries and potential candidates | | | | |
| — | European Neighbourhood Policy countries | | | | |
| — | United States of America | | | | |
| — | Russian Federation | | | | |
| — | Other countries or regions of priority notably:
—
Afghanistan, Pakistan and Iran —
Central Asian Republics —
China —
Latin American and the Caribbean (CELAC) —
Africa, in particular West Africa | — | Afghanistan, Pakistan and Iran | — | Central Asian Republics |
| — | Afghanistan, Pakistan and Iran | | | | |
| — | Central Asian Republics | | | | |
| — | China | | | | |
| — | Latin American and the Caribbean (CELAC) | | | | |
| — | Africa, in particular West Africa | | | | |
| — | Other countries depending on national and international developments | | | | |
| b. | Explore possibilities for engagement (such as bilateral dialogues, joint projects) with other non-EU countries on serious drug-related issues | | | | |
| — | Over-arching indicator 13 | | | | |
| — | Strengthened cooperation in the field of drugs with relevant partners | | | | |
| — | Dialogues organised | | | | |
| — | Declarations agreed | | | | |
| — | Programmes and Action Plans implemented | | | | |
| | 39.
Improve the Dublin Group consultative mechanism through intensified EU coordination and participation, better formulation, implementation and dissemination of its recommendations | 39. | Improve the Dublin Group consultative mechanism through intensified EU coordination and participation, better formulation, implementation and dissemination of its recommendations | Ongoing | Dublin Group
COM
EEAS
MS |
| 39. | Improve the Dublin Group consultative mechanism through intensified EU coordination and participation, better formulation, implementation and dissemination of its recommendations | | | | |
| — | Level of activity across Dublin Group structures including number of Dublin Group recommendations effectively implemented | | | | |
| — | Achieved modernisation of the Dublin Group's working methods | | | | |
| | 40.
Hold an annual dialogue on EU and MS drugs-related assistance to third countries accompanied by a written update | 40. | Hold an annual dialogue on EU and MS drugs-related assistance to third countries accompanied by a written update | From 2017 | COM
EEAS
MS |
| 40. | Hold an annual dialogue on EU and MS drugs-related assistance to third countries accompanied by a written update | | | | |
| — | Presentation by COM and EEAS to the Horizontal Drugs Group, at least once a year | | | | |
| | 41.
Ensure that the promotion and protection of human rights are fully integrated in political dialogues and in the planning and implementation of relevant drugs-related programmes and projects including through the implementation of the rights-based approach (RBA) and of tailored human rights guidance and impact assessment tool | 41. | Ensure that the promotion and protection of human rights are fully integrated in political dialogues and in the planning and implementation of relevant drugs-related programmes and projects including through the implementation of the rights-based approach (RBA) and of tailored human rights guidance and impact assessment tool | Ongoing | COM
COHOM/EEAS
MS |
| 41. | Ensure that the promotion and protection of human rights are fully integrated in political dialogues and in the planning and implementation of relevant drugs-related programmes and projects including through the implementation of the rights-based approach (RBA) and of tailored human rights guidance and impact assessment tool | | | | |
| — | Human rights effectively mainstreamed into EU external drug-related policies and actions | | | | |
| — | Human rights guidance and assessment tool implemented | | | | |
| 11.
Improve cohesiveness of EU approach and EU visibility in the United Nations (UN) and strengthen EU coordination with international bodies related to the drugs field | 11. | Improve cohesiveness of EU approach and EU visibility in the United Nations (UN) and strengthen EU coordination with international bodies related to the drugs field | 42.
Contribute to shaping the agenda on international drugs policy, including through:
a.
More affirmative action by EU and MS Delegations at the UN General Assembly and the Commission on Narcotic Drugs (CND); b.
Coordinated action by EU and MS delegations in all other UN fora addressing drug-related matters (e.g. World Health Assembly, Human Rights Council, High Level Political Forum on Sustainable Development) c.
preparation, coordination and adoption of EU common positions and joint resolutions in the UN General Assembly and the CND, including, ahead of the CND, on scheduling of substances, and ensuring that the EU speaks with one strong voice in these and other international fora; d.
promotion and monitoring the implementation of the recommendations of the 2016 UNGASS Outcome Document as a pivotal reference document for discussions of relevance to international drug policy in all pertinent fora e.
the ministerial segment to be held during the sixty-second session of CND, in Vienna in 2019; and f.
ensure the meaningful involvement of civil society and the scientific community in the review process | 42. | Contribute to shaping the agenda on international drugs policy, including through:
a.
More affirmative action by EU and MS Delegations at the UN General Assembly and the Commission on Narcotic Drugs (CND); b.
Coordinated action by EU and MS delegations in all other UN fora addressing drug-related matters (e.g. World Health Assembly, Human Rights Council, High Level Political Forum on Sustainable Development) c.
preparation, coordination and adoption of EU common positions and joint resolutions in the UN General Assembly and the CND, including, ahead of the CND, on scheduling of substances, and ensuring that the EU speaks with one strong voice in these and other international fora; d.
promotion and monitoring the implementation of the recommendations of the 2016 UNGASS Outcome Document as a pivotal reference document for discussions of relevance to international drug policy in all pertinent fora e.
the ministerial segment to be held during the sixty-second session of CND, in Vienna in 2019; and f.
ensure the meaningful involvement of civil society and the scientific community in the review process |
| 11. | Improve cohesiveness of EU approach and EU visibility in the United Nations (UN) and strengthen EU coordination with international bodies related to the drugs field | | | | |
| 42. | Contribute to shaping the agenda on international drugs policy, including through:
a.
More affirmative action by EU and MS Delegations at the UN General Assembly and the Commission on Narcotic Drugs (CND); b.
Coordinated action by EU and MS delegations in all other UN fora addressing drug-related matters (e.g. World Health Assembly, Human Rights Council, High Level Political Forum on Sustainable Development) c.
preparation, coordination and adoption of EU common positions and joint resolutions in the UN General Assembly and the CND, including, ahead of the CND, on scheduling of substances, and ensuring that the EU speaks with one strong voice in these and other international fora; d.
promotion and monitoring the implementation of the recommendations of the 2016 UNGASS Outcome Document as a pivotal reference document for discussions of relevance to international drug policy in all pertinent fora e.
the ministerial segment to be held during the sixty-second session of CND, in Vienna in 2019; and f.
ensure the meaningful involvement of civil society and the scientific community in the review process | a. | More affirmative action by EU and MS Delegations at the UN General Assembly and the Commission on Narcotic Drugs (CND); | b. | Coordinated action by EU and MS delegations in all other UN fora addressing drug-related matters (e.g. World Health Assembly, Human Rights Council, High Level Political Forum on Sustainable Development) |
| a. | More affirmative action by EU and MS Delegations at the UN General Assembly and the Commission on Narcotic Drugs (CND); | | | | |
| b. | Coordinated action by EU and MS delegations in all other UN fora addressing drug-related matters (e.g. World Health Assembly, Human Rights Council, High Level Political Forum on Sustainable Development) | | | | |
| c. | preparation, coordination and adoption of EU common positions and joint resolutions in the UN General Assembly and the CND, including, ahead of the CND, on scheduling of substances, and ensuring that the EU speaks with one strong voice in these and other international fora; | | | | |
| d. | promotion and monitoring the implementation of the recommendations of the 2016 UNGASS Outcome Document as a pivotal reference document for discussions of relevance to international drug policy in all pertinent fora | | | | |
| e. | the ministerial segment to be held during the sixty-second session of CND, in Vienna in 2019; and | | | | |
| f. | ensure the meaningful involvement of civil society and the scientific community in the review process | | | | |
| — | Over-arching indicator 13 | | | | |
| — | Number of EU statements delivered at CND and other UN fora | | | | |
| — | Number of EU common positions supported by other regions and international bodies | | | | |
| — | Number of EU common positions concerning CND decisions on scheduling of substances | | | | |
| — | Outcome of the CND decisions on scheduling of substances | | | | |
| — | Level of successful adoption of EU resolutions at UN including at the CND | | | | |
| — | Effective promotion of EU policies in the UN, including at the CND | | | | |
| — | Adoption of an EU Common Position Paper for the 2019 review process; EU contribution to the definition by the CND on the modalities for the 2019 process | | | | |
| — | Implementation of EU common position on the post-UNGASS process | | | | |
| — | Outcome of the 2019 review of the UN Political Declaration and Action Plan on International Cooperation towards an Integrated and Balanced Strategy to Counter the World Drug Problem | | | | |
| — | Progress in implementation of drug-related Sustainable Development Goals (SDGs) | | | | |
| | 43.
Strengthen partnerships with the UNODC, WHO, UNAIDS and other relevant UN agencies, international and regional bodies and organisations and initiatives (such as the Council of Europe and the Paris Pact Initiative) | 43. | Strengthen partnerships with the UNODC, WHO, UNAIDS and other relevant UN agencies, international and regional bodies and organisations and initiatives (such as the Council of Europe and the Paris Pact Initiative) | Ongoing | Council
EEAS
COM
PRES
Council WP (HDG)
EMCDDA |
| 43. | Strengthen partnerships with the UNODC, WHO, UNAIDS and other relevant UN agencies, international and regional bodies and organisations and initiatives (such as the Council of Europe and the Paris Pact Initiative) | | | | |
| — | Over-arching indicators 13, 15 | | | | |
| — | Number of information exchanges and activities between the EU and relevant international and regional bodies and organisations and initiatives | | | | |
| — | Effectiveness of partnerships with relevant bodies | | | | |
| 12.
Support the process for acceding countries, candidate countries, and potential candidates to adapt to and align with the EU acquis in the drugs field, through targeted assistance and monitoring | 12. | Support the process for acceding countries, candidate countries, and potential candidates to adapt to and align with the EU acquis in the drugs field, through targeted assistance and monitoring | 44.
Provide targeted technical assistance, and other assistance and support as necessary, to acceding countries, candidate countries, and potential candidates to facilitate their adaptation to and alignment with the EU acquis in the drugs field | 44. | Provide targeted technical assistance, and other assistance and support as necessary, to acceding countries, candidate countries, and potential candidates to facilitate their adaptation to and alignment with the EU acquis in the drugs field |
| 12. | Support the process for acceding countries, candidate countries, and potential candidates to adapt to and align with the EU acquis in the drugs field, through targeted assistance and monitoring | | | | |
| 44. | Provide targeted technical assistance, and other assistance and support as necessary, to acceding countries, candidate countries, and potential candidates to facilitate their adaptation to and alignment with the EU acquis in the drugs field | | | | |
| — | Over-arching indicator 15 | | | | |
| — | Increased compliance by countries with EU acquis | | | | |
| — | Number and quality of completed projects | | | | |
| — | National Drug Strategies and national drug coordinating structures established | | | | |

5.   Information, research, monitoring and evaluation

Contribute to a better understanding of all aspects of the drugs phenomenon and of the impact of measures in order to provide sound and comprehensive evidence for policies and actions

| Objective | Action | Timetable | Responsible party | Indicator(s) | Data collection/assessment mechanisms |
| ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------ | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| 13.
Ensure adequate investment in research, data collection, monitoring, evaluation and information exchange on all aspects of the drug phenomenon | 13. | Ensure adequate investment in research, data collection, monitoring, evaluation and information exchange on all aspects of the drug phenomenon | 45.
Promote appropriate financing of EU-level drug-related multi-disciplinary research and studies including through EU related financial programmes (2014-2020) | 45. | Promote appropriate financing of EU-level drug-related multi-disciplinary research and studies including through EU related financial programmes (2014-2020) |
| 13. | Ensure adequate investment in research, data collection, monitoring, evaluation and information exchange on all aspects of the drug phenomenon | | | | |
| 45. | Promote appropriate financing of EU-level drug-related multi-disciplinary research and studies including through EU related financial programmes (2014-2020) | | | | |
| — | Amount and type of EU funding provided across the different programmes and projects | | | | |
| | 46.
Ensure that EU-supported projects:
a.
take account of the priorities of the EU Drug Strategy and Action Plan on Drugs; b.
take account of gaps in policy formulation; c.
deliver clear added value and ensure coherence and synergy; and d.
avoid duplication with research under other programmes and bodies e.
take account of the importance of behavioural research and neuroscience( 8 ) f.
include clear indicators for measuring their impact | 46. | Ensure that EU-supported projects:
a.
take account of the priorities of the EU Drug Strategy and Action Plan on Drugs; b.
take account of gaps in policy formulation; c.
deliver clear added value and ensure coherence and synergy; and d.
avoid duplication with research under other programmes and bodies e.
take account of the importance of behavioural research and neuroscience( 8 ) f.
include clear indicators for measuring their impact | a. | take account of the priorities of the EU Drug Strategy and Action Plan on Drugs; |
| 46. | Ensure that EU-supported projects:
a.
take account of the priorities of the EU Drug Strategy and Action Plan on Drugs; b.
take account of gaps in policy formulation; c.
deliver clear added value and ensure coherence and synergy; and d.
avoid duplication with research under other programmes and bodies e.
take account of the importance of behavioural research and neuroscience( 8 ) f.
include clear indicators for measuring their impact | a. | take account of the priorities of the EU Drug Strategy and Action Plan on Drugs; | b. | take account of gaps in policy formulation; |
| a. | take account of the priorities of the EU Drug Strategy and Action Plan on Drugs; | | | | |
| b. | take account of gaps in policy formulation; | | | | |
| c. | deliver clear added value and ensure coherence and synergy; and | | | | |
| d. | avoid duplication with research under other programmes and bodies | | | | |
| e. | take account of the importance of behavioural research and neuroscience( 8 ) | | | | |
| f. | include clear indicators for measuring their impact | | | | |
| — | The inclusion of the priorities of the EU Strategy and Action Plan on Drugs in the funding and assessment criteria of EU-funded drug-related research | | | | |
| — | Number, impact, complementarity and value of EU-funded drug-related research grants and contracts awarded | | | | |
| — | Number of EU-funded drug- related articles and research reports published in peer-reviewed journals with high impact factors | | | | |
| — | Annual debate at the HDG on drug-related research projects funded by the EU including EMCDDA Scientific Committee recommendations on research priorities | | | | |
| | 47.
Promote evidence-based evaluations of policies and interventions at national, EU and international level | 47. | Promote evidence-based evaluations of policies and interventions at national, EU and international level | 2017-2020 | COM
MS
EMCDDA |
| 47. | Promote evidence-based evaluations of policies and interventions at national, EU and international level | | | | |
| — | Over-arching indicator 14 | | | | |
| — | EMCDDA guide on evaluation used to support national process | | | | |
| — | Delivery of dedicated studies into the effectiveness and impacts of EU and international drug policies | | | | |
| | 48.
Reinforce analysis (including mapping information sources) and information sharing on the relationship between drugs trafficking and:
a.
financing of terrorist groups and activities, including any overlap between the established routes for drug production and trafficking areas and conflict zones; and financing sources of terrorist cells in the EU from illicit activities, including drug trafficking; b.
migrant smuggling (building synergies with the EU Action Plan against migrant smuggling (2015-2020) that foresees research and risk analysis between smuggling and other crimes such as drug trafficking) including:
—
A focus on vulnerable migrants and their potential exploitation for drug trafficking purposes and/or as end-users of drugs, in particular minors and women. —
Exploration of any overlap between drug trafficking and migrant smuggling criminal rings, modi operandi and routes. c.
trafficking in human beings building synergies with the EU legal and policy framework addressing trafficking in human beings including the EU Strategy towards the Eradication of Trafficking in Human Beings 2012–2016 | 48. | Reinforce analysis (including mapping information sources) and information sharing on the relationship between drugs trafficking and:
a.
financing of terrorist groups and activities, including any overlap between the established routes for drug production and trafficking areas and conflict zones; and financing sources of terrorist cells in the EU from illicit activities, including drug trafficking; b.
migrant smuggling (building synergies with the EU Action Plan against migrant smuggling (2015-2020) that foresees research and risk analysis between smuggling and other crimes such as drug trafficking) including:
—
A focus on vulnerable migrants and their potential exploitation for drug trafficking purposes and/or as end-users of drugs, in particular minors and women. —
Exploration of any overlap between drug trafficking and migrant smuggling criminal rings, modi operandi and routes. c.
trafficking in human beings building synergies with the EU legal and policy framework addressing trafficking in human beings including the EU Strategy towards the Eradication of Trafficking in Human Beings 2012–2016 | a. | financing of terrorist groups and activities, including any overlap between the established routes for drug production and trafficking areas and conflict zones; and financing sources of terrorist cells in the EU from illicit activities, including drug trafficking; |
| 48. | Reinforce analysis (including mapping information sources) and information sharing on the relationship between drugs trafficking and:
a.
financing of terrorist groups and activities, including any overlap between the established routes for drug production and trafficking areas and conflict zones; and financing sources of terrorist cells in the EU from illicit activities, including drug trafficking; b.
migrant smuggling (building synergies with the EU Action Plan against migrant smuggling (2015-2020) that foresees research and risk analysis between smuggling and other crimes such as drug trafficking) including:
—
A focus on vulnerable migrants and their potential exploitation for drug trafficking purposes and/or as end-users of drugs, in particular minors and women. —
Exploration of any overlap between drug trafficking and migrant smuggling criminal rings, modi operandi and routes. c.
trafficking in human beings building synergies with the EU legal and policy framework addressing trafficking in human beings including the EU Strategy towards the Eradication of Trafficking in Human Beings 2012–2016 | a. | financing of terrorist groups and activities, including any overlap between the established routes for drug production and trafficking areas and conflict zones; and financing sources of terrorist cells in the EU from illicit activities, including drug trafficking; | b. | migrant smuggling (building synergies with the EU Action Plan against migrant smuggling (2015-2020) that foresees research and risk analysis between smuggling and other crimes such as drug trafficking) including:
—
A focus on vulnerable migrants and their potential exploitation for drug trafficking purposes and/or as end-users of drugs, in particular minors and women. —
Exploration of any overlap between drug trafficking and migrant smuggling criminal rings, modi operandi and routes. |
| a. | financing of terrorist groups and activities, including any overlap between the established routes for drug production and trafficking areas and conflict zones; and financing sources of terrorist cells in the EU from illicit activities, including drug trafficking; | | | | |
| b. | migrant smuggling (building synergies with the EU Action Plan against migrant smuggling (2015-2020) that foresees research and risk analysis between smuggling and other crimes such as drug trafficking) including:
—
A focus on vulnerable migrants and their potential exploitation for drug trafficking purposes and/or as end-users of drugs, in particular minors and women. —
Exploration of any overlap between drug trafficking and migrant smuggling criminal rings, modi operandi and routes. | — | A focus on vulnerable migrants and their potential exploitation for drug trafficking purposes and/or as end-users of drugs, in particular minors and women. | — | Exploration of any overlap between drug trafficking and migrant smuggling criminal rings, modi operandi and routes. |
| — | A focus on vulnerable migrants and their potential exploitation for drug trafficking purposes and/or as end-users of drugs, in particular minors and women. | | | | |
| — | Exploration of any overlap between drug trafficking and migrant smuggling criminal rings, modi operandi and routes. | | | | |
| c. | trafficking in human beings building synergies with the EU legal and policy framework addressing trafficking in human beings including the EU Strategy towards the Eradication of Trafficking in Human Beings 2012–2016 | | | | |
| — | Extent to which understanding is increased of the potential connections between drug trafficking and:
—
Terrorist financing —
Migrant smuggling —
Trafficking in Human Beings | — | Terrorist financing | — | Migrant smuggling |
| — | Terrorist financing | | | | |
| — | Migrant smuggling | | | | |
| — | Trafficking in Human Beings | | | | |
| — | EU and national outputs (such as reports, studies and articles addressing these topics) | | | | |
| 14.
Maintain networking and cooperation and develop capacity within and across the EU's knowledge infrastructure for information, research, monitoring and evaluation of drugs, particularly illicit drugs | 14. | Maintain networking and cooperation and develop capacity within and across the EU's knowledge infrastructure for information, research, monitoring and evaluation of drugs, particularly illicit drugs | 49.
In collaboration with relevant parties continue to provide comprehensive analyses of:
a.
the EU drug situation; b.
the dynamics of drug use within general populations and target groups c.
responses to drug use and in due course to provide an update by the EMCDDA of the 2017 overview of cannabis legislation in the EU as well as continue to monitor and report on cannabis legislations at national level and in third countries | 49. | In collaboration with relevant parties continue to provide comprehensive analyses of:
a.
the EU drug situation; b.
the dynamics of drug use within general populations and target groups c.
responses to drug use and in due course to provide an update by the EMCDDA of the 2017 overview of cannabis legislation in the EU as well as continue to monitor and report on cannabis legislations at national level and in third countries |
| 14. | Maintain networking and cooperation and develop capacity within and across the EU's knowledge infrastructure for information, research, monitoring and evaluation of drugs, particularly illicit drugs | | | | |
| 49. | In collaboration with relevant parties continue to provide comprehensive analyses of:
a.
the EU drug situation; b.
the dynamics of drug use within general populations and target groups c.
responses to drug use and in due course to provide an update by the EMCDDA of the 2017 overview of cannabis legislation in the EU as well as continue to monitor and report on cannabis legislations at national level and in third countries | a. | the EU drug situation; | b. | the dynamics of drug use within general populations and target groups |
| a. | the EU drug situation; | | | | |
| b. | the dynamics of drug use within general populations and target groups | | | | |
| c. | responses to drug use | | | | |
| — | Over-arching indicators 1-15 | | | | |
| — | Current deficits in the knowledge base established and an EU level framework developed to maximise analyses from current data holdings | | | | |
| — | Number of overviews and topic analyses on the drug situation | | | | |
| | 50.
Enhance evidence-based training for those involved in responding to the drug phenomenon | 50. | Enhance evidence-based training for those involved in responding to the drug phenomenon | 2017-2020 | MS
EMCDDA
CEPOL |
| 50. | Enhance evidence-based training for those involved in responding to the drug phenomenon | | | | |
| — | Number of initiatives at MS and EU level to train professionals in aspects of drug demand reduction and drug supply reduction | | | | |
| — | Number of initiatives at MS and EU level implemented to train professionals related to data collection and reporting of drug demand reduction and drug supply reduction | | | | |
| | 51.
Enhance data collection, research, analysis and reporting on:
a.
drug demand reduction; b.
drug supply reduction; c.
emerging trends, such as polydrug use and misuse of psychoactive medicines, that pose risks to health and safety; d.
blood-borne viruses associated with drug use including but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis; e.
psychiatric and physical co-morbidity; f.
drug problems among prisoners and the availability and coverage of drug demand reduction interventions and services in prison settings; and g.
other problems and consequences related to illicit substances as well as to polydrug use (combined use of illicit and licit substances including psychoactive medicines, alcohol and tobacco) h.
compliance of drug policies with international human rights standards and principles | 51. | Enhance data collection, research, analysis and reporting on:
a.
drug demand reduction; b.
drug supply reduction; c.
emerging trends, such as polydrug use and misuse of psychoactive medicines, that pose risks to health and safety; d.
blood-borne viruses associated with drug use including but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis; e.
psychiatric and physical co-morbidity; f.
drug problems among prisoners and the availability and coverage of drug demand reduction interventions and services in prison settings; and g.
other problems and consequences related to illicit substances as well as to polydrug use (combined use of illicit and licit substances including psychoactive medicines, alcohol and tobacco) h.
compliance of drug policies with international human rights standards and principles | a. | drug demand reduction; |
| 51. | Enhance data collection, research, analysis and reporting on:
a.
drug demand reduction; b.
drug supply reduction; c.
emerging trends, such as polydrug use and misuse of psychoactive medicines, that pose risks to health and safety; d.
blood-borne viruses associated with drug use including but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis; e.
psychiatric and physical co-morbidity; f.
drug problems among prisoners and the availability and coverage of drug demand reduction interventions and services in prison settings; and g.
other problems and consequences related to illicit substances as well as to polydrug use (combined use of illicit and licit substances including psychoactive medicines, alcohol and tobacco) h.
compliance of drug policies with international human rights standards and principles | a. | drug demand reduction; | b. | drug supply reduction; |
| a. | drug demand reduction; | | | | |
| b. | drug supply reduction; | | | | |
| c. | emerging trends, such as polydrug use and misuse of psychoactive medicines, that pose risks to health and safety; | | | | |
| d. | blood-borne viruses associated with drug use including but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis; | | | | |
| e. | psychiatric and physical co-morbidity; | | | | |
| f. | drug problems among prisoners and the availability and coverage of drug demand reduction interventions and services in prison settings; and | | | | |
| g. | other problems and consequences related to illicit substances as well as to polydrug use (combined use of illicit and licit substances including psychoactive medicines, alcohol and tobacco) | | | | |
| h. | compliance of drug policies with international human rights standards and principles | | | | |
| — | Increased availability and implementation of evidence-based and scientifically sound indicators on drug supply reduction and drug demand reduction | | | | |
| — | At MS level, extent of new research initiated on emerging trends such as polydrug use and the misuse of psychoactive medicines; blood-borne diseases associated with drug use including but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis; psychiatric and physical co-morbidity; and other problems and consequences related to both licit and illicit substances | | | | |
| — | EU-wide study carried out on drug-related community intimidation and its impact on individuals, families and communities most affected and effective responses to it | | | | |
| — | Adoption of evidence-based and scientifically sound indicators on drug problems among prisoners | | | | |
| | 52.
Improve the capacity to detect, assess and respond effectively to the emergence and use of new psychoactive substances and monitor the extent to which such new substances impact on the number and profile of users | 52. | Improve the capacity to detect, assess and respond effectively to the emergence and use of new psychoactive substances and monitor the extent to which such new substances impact on the number and profile of users | Ongoing | COM
MS
EMCDDA
Europol |
| 52. | Improve the capacity to detect, assess and respond effectively to the emergence and use of new psychoactive substances and monitor the extent to which such new substances impact on the number and profile of users | | | | |
| — | Over-arching indicator 6 | | | | |
| — | Extent of new epidemiological, pharmacological and toxicological research initiated on new psychoactive substances and supported by MS and EU Research programmes | | | | |
| — | Extent of information, best practice and intelligence exchange | | | | |
| — | Extent of sharing by toxicology laboratories and by Research Institutes of toxicological and health data analyses on new psychoactive substances | | | | |
| | 53.
Strengthen efforts to share forensic science data, including support on the identification of new psychoactive substances, laboratory reference standards on new psychoactive substances, and the development of a common methodology for the identification of new substances by enhancing cooperation with the Commission's Joint Research Centre, and through existing networks, such as the Drugs Working Group of the European Network of Forensic Science Institutes in the framework of the JHA Council Conclusions on the Vision for European Forensic Science 2020 and the Customs Laboratories European Network | 53. | Strengthen efforts to share forensic science data, including support on the identification of new psychoactive substances, laboratory reference standards on new psychoactive substances, and the development of a common methodology for the identification of new substances by enhancing cooperation with the Commission's Joint Research Centre, and through existing networks, such as the Drugs Working Group of the European Network of Forensic Science Institutes in the framework of the JHA Council Conclusions on the Vision for European Forensic Science 2020 and the Customs Laboratories European Network | 2017-2020 | COM
MS
EMCDDA |
| 53. | Strengthen efforts to share forensic science data, including support on the identification of new psychoactive substances, laboratory reference standards on new psychoactive substances, and the development of a common methodology for the identification of new substances by enhancing cooperation with the Commission's Joint Research Centre, and through existing networks, such as the Drugs Working Group of the European Network of Forensic Science Institutes in the framework of the JHA Council Conclusions on the Vision for European Forensic Science 2020 and the Customs Laboratories European Network | | | | |
| — | Over-arching indicator 15 | | | | |
| — | Extent of sharing of forensic science data on new psychoactive substances, supporting the identification of new psychoactive substances | | | | |
| — | Ease of access to laboratory reference standards by forensic science laboratories, customs laboratories and institutes | | | | |
| — | Progress on development of a common methodology for the identification of new psychoactive substances | | | | |
| | 54.
Improve and increase the ability to identify, assess and respond at MS and EU levels to (a) behavioural changes in drug consumption; and (b) to drug-related epidemic outbreaks | 54. | Improve and increase the ability to identify, assess and respond at MS and EU levels to (a) behavioural changes in drug consumption; and (b) to drug-related epidemic outbreaks | Ongoing | MS
EMCDDA
ECDC |
| 54. | Improve and increase the ability to identify, assess and respond at MS and EU levels to (a) behavioural changes in drug consumption; and (b) to drug-related epidemic outbreaks | | | | |
| — | Number and effectiveness of new drug-related public health initiatives developed and implemented | | | | |
| — | Number and effectiveness of existing measures and initiatives that are adjusted to take account of drug consumption or epidemic outbreaks | | | | |
| — | Number and impact of early warning reports, risk assessment and alerts | | | | |
| 15.
Enhance dissemination of monitoring, research and evaluation results at EU and national level | 15. | Enhance dissemination of monitoring, research and evaluation results at EU and national level | 55.
Member States continue to support EU monitoring and information exchange efforts, including cooperation with, and adequate support for, Reitox National Focal Points
a.
Organisation of European events focused on the transfer and dissemination of knowledge from research to policy makers and professionals | 55. | Member States continue to support EU monitoring and information exchange efforts, including cooperation with, and adequate support for, Reitox National Focal Points
a.
Organisation of European events focused on the transfer and dissemination of knowledge from research to policy makers and professionals |
| 15. | Enhance dissemination of monitoring, research and evaluation results at EU and national level | | | | |
| 55. | Member States continue to support EU monitoring and information exchange efforts, including cooperation with, and adequate support for, Reitox National Focal Points
a.
Organisation of European events focused on the transfer and dissemination of knowledge from research to policy makers and professionals | a. | Organisation of European events focused on the transfer and dissemination of knowledge from research to policy makers and professionals | | |
| a. | Organisation of European events focused on the transfer and dissemination of knowledge from research to policy makers and professionals | | | | |
| — | Open-access outputs from EU funded studies disseminated | | | | |
| — | Extent to which Reitox National Focal Points funding and other resources match requirements | | | | |
| — | Number and effectiveness of Reitox National Focal Points dissemination initiatives | | | | |
| — | Number of EU events organised on the transfer and dissemination of knowledge from research to policy makers and professionals | | | | |

---

( 1 )  Evidence-based should be read in this context as ‘based on available scientific evidence and experience’.

( 2 )  Council conclusions on the implementation of the EU Action Plan on Drugs 2013-2016 regarding minimum quality standards in drug demand reduction in the European Union 11985/15.

( 3 )  MAOC (N), based in Lisbon, is an initiative by seven EU Member countries: France, Ireland, Italy, Spain, Netherlands, Portugal and the UK, and is co-funded by the Internal Security Fund of the European Union. The Centre provides a forum for multi-lateral cooperation to suppress illicit drug trafficking by sea and air.

( 4 )  Council conclusions on improving the monitoring of drug supply in the European Union 15 November 2013.

( 5 )  Directive 2014/42/EU of the European Parliament and of the Council on the freezing and confiscation of instrumentalities and proceeds of crime in the European Union; Council Decision 2007/845/JHA concerning cooperation between Asset Recovery Offices of the Member States in the field of tracing and identification of proceeds of, or other property related to, crime; Council Framework Decision 2006/783/JHA on the application of the principle of mutual recognition to confiscation orders. Council Framework Decision 2003/577/JHA on the execution in the European Union of orders freezing property or evidence, Commission proposal for a Regulation of the European Parliament and of the Council on the mutual recognition of freezing and confiscation orders COM(2016) 819; Council Framework Decision 2005/212/JHA on confiscation of crime-related proceeds, instrumentalities and property; Council Framework Decision 2003/577/JHA on the execution in the European Union of orders freezing property or evidence.

( 6 )  Directive (EU) 2015/849 of the European Parliament and of the Council on the prevention of the use of the financial system for the purposes of money laundering or terrorist financing, amending Regulation (EU) No 648/2012 of the European Parliament and of the Council, and repealing Directive 2005/60/EC of the European Parliament and of the Council and Commission Directive 2006/70/EC; Council Framework Decision 2001/500/JHA on money laundering, the identification, tracing, seizing and confiscation of instrumentalities and the proceeds of crime. Commission proposal for a Directive of the European Parliament and of the Council on countering money laundering by criminal law COM(2016) 826. Regulation (EU) 2015/847 of the European Parliament and of the Council on information accompanying transfers of funds and repealing Regulation (EC) No 1781/2006; Regulation (EC) No 1889/2005 of the European Parliament and of the Council on controls of cash entering or leaving the Community. Commission proposal for a Regulation of the European Parliament and of the Council on controls on cash entering or leaving the Union and repealing Regulation (EC) No 1889/2005.

( 7 )  Council Framework Decision 2004/757/JHA of 25 October 2004 laying down minimum provisions on the constituent elements of criminal acts and penalties in the field of illicit drug trafficking, as regards the definition of drug.

( 8 )  Under Horizon 2020 (2014-2020), some EUR 27 million have already been allocated to projects addressing drug addiction and include behavioural research and neuroscience.

---

ANNEX I 15 over-arching indicators for the EU Action Plan on Drugs 2017-2020( 1 ) 1.
Percentage of population who use drugs currently (within last month), used drugs recently (within last year), and who have ever used (lifetime use) by drug and age group (EMCDDA General Population Survey) 2.
Estimated trends in the prevalence of problem and injecting drug use (EMCDDA Problem Drug Use) 3.
Trends in drug induced deaths and mortality amongst drug users (according to national definitions) (EMCDDA Drug-related Deaths) 4.
Prevalence and incidence, among injecting drug users, of infectious diseases attributable to drug use, including HIV and viral Hepatitis, sexually transmittable diseases and tuberculosis (EMCDDA Drug-related Infectious Diseases) 5.
Trends in the age of first use of illicit drugs (European School Survey Project on Alcohol and Drugs (ESPAD), Health Behaviour in School-aged Children (HBSC) and General Population Drug Use Survey (EMCDDA Key Epidemiological Indicator) 6.
Trends in numbers of people entering drug treatment (EMCDDA Treatment Demand) and the estimated total number of people in drug treatment (EMCDDA Treatment Demand and Health and Social Responses) 7.
Trends in number of and quantities of seized illicit drugs (EMCDDA Drug Seizures: cannabis incl. herbal cannabis, heroin, cocaine, crack cocaine, amphetamine, methamphetamine, ecstasy, LSD and other substances) 8.
Trends in retail price and purity of illicit drugs (EMCDDA Price and Purity: cannabis incl. herbal cannabis, heroin, cocaine, crack cocaine, amphetamine, methamphetamine, ecstasy, LSD, other substances and composition of drug tablets) 9.
Trends in the number of initial reports of drug law offences, by drug and type of offence (supply vs use/possession) (EMCDDA Drug Offences) 10.
Prevalence of drug use amongst prisoners (EMCDDA Drug Use in Prisons) 11.
Assessment of availability, coverage and quality of services and interventions in the areas of prevention, harm reduction, social integration and treatment. (EMCDDA Health and Social Responses) 12.
Evidence-based interventions on prevention, treatment, social integration and recovery and their expected impact on drug use prevalence and problem drug use (EMCDDA Best Practice Portal) 13.
Strong dialogue and cooperation, in the drugs related field, with other regions, third countries, international organisations and other parties (EEAS reporting) 14.
Developments in national drug strategies, evaluations, legislation, coordination mechanisms and public expenditure estimates in EU Member States (EMCDDA) 15.
Early Warning System on new psychoactive substances (EMCDDA/Europol) and Risk Assessment on new psychoactive substances (EMCDDA) ( 1 )  These indicators are based on existing reporting systems that pre-date the objectives of the current EU drug strategy and action plan, but provide the most comprehensive set of EU-level resources to support their monitoring and evaluation.

---

ANNEX II Glossary of acronyms CCWP
Council of the EU — Customs Cooperation Working Party CELAC
Comunidad de Estados Latinoamericanos y Caribeños (Community of Latin American and Caribbean States) CEPOL
European Police College CND
Commission on Narcotic Drugs (UN) COAFR
Council of the EU — Africa Working Party COASI
Council of the EU — Asia-Oceania Working Party COEST
Council of the EU — Working Party on Eastern Europe and Central Asia COHOM
Council of the EU — Working Party on Human Rights COLAC
Council of the EU — Working Party on Latin America COM
European Commission CONUN
Council of the EU — United Nations Working Party COSCE
Council of the EU — Working Party on OSCE and the Council of Europe COSI
Council of the EU — Standing Committee on Operational Cooperation on Internal Security COTRA
Council of the EU — Working Party on Transatlantic Relations (Canada and the USA) Council WP
Council Working Party COTER
Council of the EU — Working Party on Terrorism (International Aspects) COWEB
Council of the EU — Working Party on the Western Balkans Region CUG
Council of the EU — Customs Union Group DROIPEN
Council of the EU — Working Party on Substantive Criminal Law ECDC
European Centre for Disease Control EEAS
European Union External Action Service EMA
European Medicines Agency EMCDDA
European Monitoring Centre for Drugs and Drug Addiction EMPACT
European Multidisciplinary Platform against Criminal Threats ENFSI
European Network of Forensic Science Institutes ERA-net
European Research Area — Network ERANID
European Research Area Network on Illicit Drugs ESPAD
European School Survey Project on Alcohol and Drugs EU
European Union EUROJUST
European Judicial Cooperation Unit EUROPOL
European Union Agency for Law Enforcement Cooperation EU SOCTA
EU Serious and Organised Crime Threat Assessment Frontex
European Agency for the Management of Operational Cooperation at the External Borders of the Member States of the European Union HBSC
Health Behaviour in School Aged Children survey HCV
Hepatitis C virus HDG
Council of the EU — Horizontal Working Party on Drugs HIV
Human immunodeficiency virus HLWG
Council of the EU — High-Level Working Group on Asylum and Migration INCB
International Narcotics Control Board (UN) JHA
Justice and Home Affairs LGBTI
Lesbian, Gay, Bisexual, Transgender/Transsexual and Intersexed LSD
Lysergic acid diethylamide MAOC (N)
The Maritime Analysis and Operations Centre MASPs
Multiannual Strategic Plans (Europol) MOU
Memorandum of Understanding MS
Member State NPS
New psychoactive substances PEN
UNODC/INCB developed Pre-Export Notification Online System PICS
Precursors Incident Communication System PRES
Rotating Presidency of the Council of the European Union PRES Trio
Grouping of three consecutive rotating Presidencies of the Council of the European Union Reitox
Réseau Européen d’Information sur les Drogues et les Toxicomanies SOCTA
Serious and Organised Crime Threat Assessment TWP
Council of the EU — Working Party on Terrorism UN
United Nations UNAIDS
Joint United Nations Programme on HIV/AIDS UNGASS
United Nations General Assembly Special Session UNODC
United Nations Office on Drugs and Crime UNDP
United Nations Development Programme WHO
World Health Organisation (UN)

---